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Abstract The use of novel drugs and chemicals requires
reliable data on their potential toxic effects on humans.
Current test systems are mainly based on animals or in
vitro–cultured animal-derived cells and do not or not suf-
ﬁciently mirror the situation in humans. Therefore, in vitro
models based on human pluripotent stem cells (hPSCs)
have become an attractive alternative. The article sum-
marizes the characteristics of pluripotent stem cells,
including embryonic carcinoma and embryonic germ cells,
and discusses the potential of pluripotent stem cells for
safety pharmacology and toxicology. Special attention is
directed to the potential application of embryonic stem
cells (ESCs) and induced pluripotent stem cells (iPSCs) for
the assessment of developmental toxicology as well as
cardio- and hepatotoxicology. With respect to embryotox-
icology, recent achievements of the embryonic stem cell
test (EST) are described and current limitations as well as
prospects of embryotoxicity studies using pluripotent stem
cells are discussed. Furthermore, recent efforts to establish
hPSC-based cell models for testing cardio- and hepato-
toxicity are presented. In this context, methods for differ-
entiation and selection of cardiac and hepatic cells from
hPSCs are summarized, requirements and implications
with respect to the use of these cells in safety pharmacol-
ogy and toxicology are presented, and future challenges
and perspectives of using hPSCs are discussed.
Keywords Embryonic stem (ES) cells  Embryonic
carcinoma (EC) cells  Induced pluripotent stem (iPS)
cells  Mouse  Human  Pluripotency  Differentiation 
Embryonic stem cell test (EST)  In vitro embryotoxicity 
Cardiotoxicity  Hepatotoxicity
Introduction
During their whole life, human beings are exposed to
xenobiotics, such as diverse chemical substances, pharma-
ceutical drugs and other potentially hazardous chemical and
physical environmental factors. These expositions may hold
seriousrisksfortheindividualandmayleadtotissue-speciﬁc
damages,butmayalsoresultinthedevelopmentoftumours.
In the case that early embryos or germ cells are affected,
cytotoxic, mutagenic or teratogenic xenobiotics may induce
embryotoxic effects or malformations of the offspring.
At present, a hierarchy of accepted test systems using in
vitro and in vivo models are in use to analyse the potential
toxic effects of pharmaceutical drugs and chemicals
(OECD 2008; Stummann et al. 2009a; reviewed in Vojnits
and Bremer 2010).
Many toxicological test systems are problematic,
because toxicity tests using animals are not representative
for human beings due to species-speciﬁc pharmaco-toxi-
cological effects. Such inter-species differences were
detected for example, in the cases of 13-cis retinoic acid
(Anon 1987; Hendrickx 1998) and of thalidomide (Nau
1990; Nau 1993; Tzimas et al. 1994). Speciﬁcally, the
dramatic consequences of the teratogenic effects of tha-
lidomide in human beings urgently led to the need of new
and optimized human-speciﬁc test systems.
Another aspect is the high number of animals that are
required for toxicology testing. For example, the necessity
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chemical compounds under the REACH (Registration,
Evaluation, Authorisation and Restriction of Chemicals)
programme of the European Union is expected to require
up to 10 million experimental animals (Gilbert 2010). In
addition, animal tests are not adequately standardized.
While human cellular test systems would overcome the
problem of species speciﬁcity, in vitro–cultured human
immortalized cell lines do not represent normal cell types,
and human primary cells cultured in vitro usually loose
their tissue-speciﬁc functions.
The recent applications of pluripotent stem cells and
their derivatives in toxicology and drug research provide
new alternatives to the standard routine tests performed by
the industry and offer new strategies for chemical safety
assessment (reviewed in Laustriat et al. 2010; Trosko and
Chang 2010). Pluripotent stem cells (PSCs) are character-
ized by unique capacities of self-renewal and differentia-
tion and have signiﬁcant advantages in comparison with
somatic cells. PSCs are available as undifferentiated
embryonic stem cells (ESCs) and can be cultured in vitro as
permanent lines. Speciﬁcally, human ESCs (hESCs)
established from surplus embryos after in vitro fertilization
are available with more than thousand individual cell lines
(Lo ¨ser et al. 2010).
The most important and relevant factor for toxicity
testing is the functional capacity of the in vitro–cultured
cells. ESCs do not need immortalization to maintain pro-
liferation capacity and ESC derivatives are functional in
vitro and after transplantation in vivo. ESCs recapitulate in
vitro early processes of embryonic development and show
tissue-speciﬁc expression proﬁles. ESCs are amenable to
genetic modiﬁcations, and genetic markers for selection
and cell enrichment can be introduced into the cells. In
combination with three-dimensional (3D) culture supported
by extracellular matrix (ECM) proteins, human stem cell-
based systems can mimic the microenvironment of the in
vivo niche, thus providing adequate human-speciﬁc models
for pharmaco-toxicology (reviewed in Trosko and Chang
2010).
One of the major problems for the pharmaceutical
industry is the late-stage attrition of novel compounds. For
example, between 1991 and 2000 only 11% of compounds
that entered a clinical trial were registered, and even after
registration 23% of compounds failed. Safety issues
accounted for 30% of late attrition and are, in addition to
late manifestation of low efﬁcacy, a major hurdle in the
development and market introduction of novel drugs (Kola
and Landis 2004). Consequently, there is an urgent need
for improved test systems that have the capacity to predict
toxicity in a human-speciﬁc manner and in an early phase
of drug development.
While initial hopes raised by hESCs were directed
towards their potential use in replacement therapies, the
focus of research has now shifted to the development of
pluripotent cell-based models for drug research, toxico-
logical test systems and disease modelling in vitro. Of the
top 20 pharmaceutical companies, 14 (70%) have launched
research activities involving stem cells and 64% of those
are dealing with hESCs (Jensen et al. 2009). Collaborative
research activities between large pharmaceutical compa-
nies and research institutions or small start-up companies
have been initiated within the last years to develop hPSC-
based in vitro systems for drug discovery and predictive
toxicology (Baker 2010). The increasing interest of the
pharmaceutical industry in using pluripotent human stem
cells in safety pharmacology and toxicology is also illus-
trated by collaborative programmes between the industry
and research institutions on the development of hPSC-
based in vitro test systems, such as the consortium Stem
Cells for Safer Medicine (SC4SM; Jha 2007).
The following article will discuss the unique properties
of different types of pluripotent stem cells for toxicological
studies with special consideration of hPSCs and their use in
developmental as well as in cardiac and hepatic toxicology.
Future developments may also result in the establishment
of test systems using hPSC-derived keratinocytes (Green
et al. 2003; Guenou et al. 2009; reviewed in Laustriat et al.
2010), ﬁbroblasts (Cao et al. 2008) or neural cells (Zeng
et al. 2006; Yla ¨-Outinen et al. 2010). Here, we concentrate
on current efforts to establish hPSC-based models for
studies of cardiotoxicity and hepatotoxicity: both cell types
are being applied to many toxicology studies so far and are
good examples to demonstrate the potential and the current
problems of stem cell-based in vitro toxicological test
systems. With respect to ethical and legal considerations of
using hESCs for research and commercial applications we
refer to national (e.g. German Stem Cell Act 2002; NIH
Guidelines 2009) and international guidelines (e.g. ISSCR
Guidelines 2006; Guidelines of the European Group on
Ethics in Science 2007) and to published articles (Leist
et al. 2008).
Characteristics of in vitro–cultured pluripotent stem
cells
Embryonic carcinoma (EC) cells
The ﬁrst pluripotent stem cells were detected as the stem
cells of testicular germ cell tumours in speciﬁc strains
(Sv129/ter) of mice, called teratocarcinomas (Stevens and
Little 1954; Stevens 1964; Stevens 1970). The tumours
contained embryonic carcinoma (EC) cells, which were
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fulﬁlling the criteria of being a stem cell. Besides testicular
teratomas, mouse strains that spontaneously develop
ovarian teratomas as result of defective oocyte develop-
ment also were described (Andrews 2002).
Teratocarcinoma-derived EC cells were transferred to in
vitro culture and established as permanent cell lines, which
proliferated indeﬁnitely and retained the ability to differ-
entiate in vitro into various cell types (Kahan and Ephrussi
1970; Evans 1972; Jakob et al. 1973). EC cells have been
cultivated in the undifferentiated state on mouse embryonic
ﬁbroblasts (MEF) used as feeder layer (FL) cells and dif-
ferentiated by treatment with substances, such as retinoic
acid (RA) or dimethyl sulfoxide (DMSO) and by cultiva-
tion in ‘‘hanging drops’’ or in suspension to form cell
aggregates called ‘‘embryoid bodies’’ (EBs). EBs are not
embryo-derivatives, but are composed of progenitor cells
of all three primary germ layers, which are irregularly
arranged in the aggregates. After in vitro differentiation of
EC cells with chemical inducers, tissue-speciﬁc genes are
expressed and specialized cells including developing heart,
skeletal muscle, cartilage, or nerve cells are formed
(McBurney et al. 1982; Wobus et al. 1994b).
Using this cellular model, for the ﬁrst time, embryonic
development could be studied under in vitro conditions, but
deﬁnitive pluripotency, that is in vivo development into
both somatic and germ line cells, has not been shown. To
test the developmental capacity, EC cells were transplanted
into mouse blastocysts and after transfer of the blastocysts
into the uterus of pseudo-pregnant foster mothers, resulted
in chimeric mice, in which variable somatic tissues par-
tially originated from EC cells (=‘‘injection chimeras’’;
Brinster 1974). However, EC cells did not colonize the
germ line and frequently gave rise to the formation of
tumours in the offspring (Papaioannou et al. 1978), limiting
their further use in developmental biology. Obviously, due
to the formation of chromosome and gene mutations that
appeared during the extra-uterine growth of embryonic
cells as teratocarcinomas, the tissue participation of EC
cells in chimeras was limited and tumours developed in the
animals. However, EC cells are still used as cellular in vitro
model. Speciﬁcally, human EC cells isolated from human
testicular or ovarian teratocarcinomas have been applied to
generate human-speciﬁc cell surface antigens (Andrews
2002).
Embryonic stem (ES) and embryonic germ (EG) cells
Instead of cultivating embryo-derived EC cells of mice, in
1981 early mouse embryos were directly transferred into
tissue culture and established as permanent embryonic stem
(ES) cells (Evans and Kaufman 1981; Martin 1981). ESCs
have been cultured on MEF-FL cells, and after the
identiﬁcation of the differentiation-inhibiting activity
(DIA) that represented the leukaemia-inhibitory factor
(LIF; Smith et al. 1988; Williams et al. 1988), different
murine (m) ESC lines were established, which were able to
proliferate and differentiate into cell types of all three
primary germ layers. The cells formed in vitro functional
cells of the heart, skeletal muscle, nerve system, blood,
vascular, liver, pancreas and other tissues, thereby reca-
pitulating early developmental processes (reviewed in
Wobus and Boheler 2005). Later on, ESCs were also
induced to differentiate into female (Hu ¨bner et al. 2003)
and male (Toyooka et al. 2003) germ-like cells.
The true pluripotency of mESCs was shown by injection
into blastocysts (Bradley et al. 1984), a technique that was
later modiﬁed by aggregating ESCs and blastomeres, called
the ‘‘sandwich technique’’ (Nagy et al. 1993) or ‘‘tetraploid
embryo complementation’’ (Eggan et al. 2001). These
methods allowed the generation of offspring that com-
pletely originated from ESCs. Furthermore, techniques for
the genetic manipulation of ESCs by introducing genes
(gain-of-function) or selectively turning off genes (loss-of-
function) were established (reviewed in Wobus and Boh-
eler 2005). In gene-targeting (loss-of-function) experi-
ments, ESCs served as vehicle for the selective inactivation
of genes by homologous recombination (Thomas and
Capecchi 1987), which so far resulted in the creation of
more than thousand ‘‘knock-out mice’’ with speciﬁc
genetic defects.
At that time, only a few groups analysed the in vitro
differentiation of mESCs. This changed in 1998, when
James Thompson succeeded in the establishment of the
ﬁrst human (h) ESC lines from the inner cell mass (ICM) of
human blastocysts (Thomson et al. 1998). hESCs show
indeﬁnite proliferation on FL cells, a normal karyotype and
high developmental capacity in vitro (Reubinoff et al.
2000; reviewed in Stojkovic et al. 2004; Wobus and Boh-
eler 2005; Murry and Keller 2008). The pluripotency of
hESCs is usually tested by teratoma formation after
transplantation into immunodeﬁcient mice. The generation
of specialized cell types from hESCs opened the perspec-
tive of generating functional human cells for regenerative
therapies.
At about the same time as the ﬁrst hESC derivation,
human embryonic germ (EG) cells were established from
5- to 7-week-old aborted human foetuses (Shamblott et al.
1998). Human EG cells showed multi-lineage differentia-
tion potential, but limited proliferation and could be
propagated only as EB derivatives. This is in contrast to
murine EG cells, which were already generated in 1992 by
in vitro culture of primordial germ cells from 9.5 to 11.5 d
p.c. mouse embryos (Matsui et al. 1992; Resnick et al.
1992; Labosky et al. 1994). Murine EG cells showed
properties similar to those of mESCs and were able to re-
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1994, see Table 1). When human EG cell-differentiated
neural derivatives were transplanted into an animal model
for neurorepair, they showed some regenerative potential
(Kerr et al. 2003), suggesting that hEG cells might possibly
be an alternative to hESCs for therapeutic use. However,
the difﬁcult isolation from human foetuses and the limited
proliferative capacity restrict the applicability of hEG cells.
It should be also mentioned that murine germ line stem
cells were also isolated from adult testes and cultivated as
spermatogonial stem cells (SSCs, Guan et al. 2006). These
cells showed multi-lineage potential in vitro, but no germ
line participation, whereas another germ cell-derived
murine stem cell line showed true pluripotency (Ko et al.
2009). However, the derivation of pluripotent stem cell
lines from adult human testis (Conrad et al. 2008) has not
been repeated so far and is controversial (Ko et al. 2010).
Because of intensive public and scientiﬁc discussion on
ethical implications of destroying early embryos in the
process of hESC derivation, alternative sources for human
pluripotent stem cell lines have been exploited. For
example, hESC lines have also been obtained from single
blastomeres of human embryos without embryo destruction
(Chung et al. 2008). In addition, developmentally arrested
embryos or clinically unsuitable embryos found to be
aneuploid on preimplantation genetic screening (PGS)
were used to produce hESCs (Zhang et al. 2006; Peura
et al. 2007; Peura et al. 2008; Narwani et al. 2010).
Interestingly, the majority of embryos with chromosomal
aneuploidies resulted in genetically normal hESC lines,
suggesting mosaicism of preimplantation human embry-
onic cells (Peura et al. 2008; Narwani et al. 2010). At
present, there are more than 100 hESC lines derived from
clinically unsuitable embryos analysed by preimplantation
genetic diagnosis (PGD) for genetic alterations linked to
heritable diseases. These ‘‘disease-speciﬁc’’ hESC lines
(overview in Lo ¨ser et al. 2010) are considered as valuable
cellular models for investigating the pathogenesis of
hereditary diseases and for establishing novel diagnostic
and therapeutic strategies (reviewed in Colman and Dree-
sen 2009).
As mentioned earlier, the ability of pluripotent cells to
grow in vitro for a prolonged time allowed the introduction
of genes into the genome (gain-of-function) or the inacti-
vation of preselected genes by gene targeting via homol-
ogous recombination (loss-of-function). Both techniques
are routine strategies for mouse ESCs and allowed to
analyse the effects of constitutively expressed genes (e.g.
Rohwedel et al. 1995; Blyszczuk et al. 2003) or of gene
inactivation on in vitro differentiation (e.g. Fassler et al.
1996; reviewed in Prelle et al. 2002; Wobus and Boheler
2005). The in vitro loss-of-function strategy was extremely
helpful to analyse the molecular and cellular properties of
knock-out murine ESCs leading to embryonic lethality in
vivo. For example, b1 integrin-deﬁcient embryos are dying
around the time of implantation, but the role of b1 integrin
Table 1 Properties of mouse and human pluripotent cell populations grown in vitro (modif. according to Pera and Tam 2010 and Durcova-Hills
et al. 2008)
Types of
stem cells
Stem cell-associated genes Cell surface markers Response to factors Developmental
potential
Oct4 Nanog Sox2 Klf4 Dppa3 Rex1 Gbx2 Fgf5 SSEA1 SSEA3
SSEA4
Alkaline
phosphatase
LIF Nodal and/
or activin
FGF2 Teratoma
formation
Chimaera
formation
Mouse EC
cells
?? ???? ??? ? ? – ? –? –? – ? – (only
somatic)
Mouse ES
cells
?? ??? ?? – ? – ?? –# – ??
Mouse EG
cells
?? ??? ??– ? ? – ?? –? ?? ?
Mouse
EPL
cells
?? ?ND – – – ?? – ?? §N D N D ? –
Mouse
EpiSCs
?? ?–– – – ?? –– – ?? & ? –
Human EC
cells
?? ??? ? ?? – ?? – ? ND!
Human ES cells ?? ??? ?? –– ?? – ?? ? ND!
?, The gene or cell surface marker is expressed, the growth factors are required for self-renewal or the cells form teratomas or chimaeras; –, the gene or cell
surface marker is not expressed, the indicated factors are not required for self-renewal, or the cells do not form tumours or chimaeras, ND, not done; ND!,
cannot to be done for obvious ethical reasons!
# One study shows long-term self-renewal;
§ EPL cells grown in LIF revert to an ES-like state;
& EpiSCs are derived and maintained in the presence of these
factors, but dependence on the factors for self-renewal has not been rigorously examined
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in vitro differentiation into cardiac, skeletal muscle and
neural cells (Fassler et al. 1996; Rohwedel et al. 1998).
Further advances in genetic modiﬁcations of ESCs were
integration-independent extra-chromosomal expression,
recombineering and RNA interference (reviewed in Wobus
and Boheler 2005; Zeng and Rao 2008). These advanced
genetic modiﬁcation methods require the establishment of
further strategies, including vector design (DNA, BACs,
YACs), gene expression from constitutive or regulated
promoters, positive or negative selection, and the estab-
lishment of speciﬁc transfection routes.
Whereas the technique of homologous recombination in
mESCs resulted in thousands of knock-out animals, the
adaptation of this technique to hESCs is difﬁcult, partially
due to low homologous recombination efﬁciencies and
targeting to non-expressed genes. Homologous recombi-
nation in hESCs was ﬁrst demonstrated by Zwaka and
Thomson (2003) using both knock-out and knock-in strat-
egies. Inactivation was successful for the hypoxanthin
phosphoribosyl transferase (hprt) 1 gene since it is located
on the X chromosome, and inactivation of the hprt1 gene
was achieved in the male (XY) hESC line H1.1. For the
knock-in strategy, oct4/gfp reporter hESC lines were cre-
ated, in which the GFP reporter gene was inserted into one
allele of the pluripotency gene Oct4. The homologous
recombination efﬁciency for both genes was 10
-5 to 10
-6,
which is in the range of those observed in mESCs (Zwaka
and Thomson 2003). There are only few other examples of
successful gene targeting in hESCs until now (e.g. Urbach
et al. 2004; Irion et al. 2007; Table 2), and the low efﬁ-
ciency of homologous recombination is still limiting studies
on genetically modiﬁed hESCs (reviewed in Nakayama
2010; Tenzen et al. 2010). More recently, zinc-ﬁnger nuc-
leases enhanced homologous recombination was shown to
work efﬁciently for introducing genetic modiﬁcations into
speciﬁc sites of hESCs (Lombardo et al. 2007; Hockemeyer
et al. 2009; Zou et al. 2009). In addition, RNAi technology
and gene trapping were successfully applied to hESCs to
silence gene function (Zaehres et al. 2005; reviewed in Ben-
Nun and Benvenisty 2006; see also Zeng and Rao 2008).
The comparative investigation of mouse and human
ESCs revealed signiﬁcant differences between both spe-
cies. hESCs grow independent of LIF (but need FL cells or
FL-conditioned medium) but are dependent on FGF2- and
Activin/Nodal-controlled signalling pathways (reviewed in
Schnerch et al. 2010). hESCs partially express different
cell surface molecules than mESCs (e.g. SSEA-3/4, instead
of SSEA-1). Comparative gene expression analyses indi-
cated a higher similarity of hESCs with murine postim-
plantation-derived epiblast stem cells (mEpiSC) than with
blastocyst-derived mESCs (Brons et al. 2007; Tesar et al.
2007).
In summary, both murine and human ESCs resemble
pluripotent cells of the ICM, multiply almost indeﬁnitely
and differentiate into derivatives of all three primary germ
layers. Thus, ESCs fulﬁl the criteria of ‘‘true’’ stem cells
and represent an ‘‘immortal’’ cell population, which in
contrast to somatic cells of the body (under adequate cul-
ture conditions) may be maintained without signs of age-
ing. However, due to their unlimited proliferation in vitro
and a high telomerase activity, ESCs may also behave as
tumour cells (reviewed in Wobus 2010). Speciﬁcally, for
hESCs the only test for pluripotency includes the trans-
plantation of cells into immunodeﬁcient mice resulting in
teratoma (or, in rare cases, teratocarcinoma) formation. On
the other hand, in vitro differentiation into functional cell
derivatives of the three germ layers opens the unique
potential for applications of hESCs as cellular model in
pharmaco-toxicology and developmental toxicology.
Induced pluripotent stem (iPS) cells
An alternative pluripotent stem cell type of signiﬁcance for
toxicological studies has been introduced only a few years
ago: In 2006, Shinja Yamanaka established so-called
induced pluripotent stem cells (iPSCs) by reprogramming
murine ﬁbroblasts by viral transfer of four genes associated
with pluripotency, Oct4, Sox2, Klf4 and c-Myc (Takahashi
and Yamanaka 2006). These data demonstrated that the
specialized somatic cells can be reversed into a pluripotent
state in vitro. Reprogramming of in vitro–cultured mam-
malian cells to pluripotency occurred solely by expression
of virally transferred pluripotency-associated genes. The
robustness of the method was independently conﬁrmed by
three groups (Maherali et al. 2007; Okita et al. 2007;
Wernig et al. 2007) and only 1 year later, reprogramming
of human ﬁbroblasts into human iPS cells was achieved
(Takahashi et al. 2007; Yu et al. 2007). Meanwhile,
reprogramming of diverse somatic cell types of various
mammalian species into iPS cells with proliferation, mor-
phology, gene expression, imprinting and chromatin pro-
ﬁles similar to ESCs has been shown (reviewed in
Nishikawa et al. 2008; Amabile and Meissner 2009). Plu-
ripotency of murine iPS cells was conﬁrmed by blastocyst
injection or ‘‘tetraploid embryo complementation’’, which
resulted in the contribution of the iPS cells to embryo
formation (Maherali et al. 2007; Wernig et al. 2007) and,
only 2 years later, in the birth of living mice completely
derived from somatic donor cells (Boland et al. 2009; Kang
et al. 2009; Zhao et al. 2009b).
Progress in iPS cell generation was achieved by estab-
lishing techniques that avoid stable integration of foreign
genetic material into the host cell genome in the process of
reprogramming, for example, by transgene removal fol-
lowing viral transduction of the pluripotency genes in iPS
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123cells (Kaji et al. 2009; Soldner et al. 2009; Woltjen et al.
2009), the generation of iPS cells using non-integrating
viral vectors or plasmids to provide the reprogramming
factors (Stadtfeld et al. 2008; Yu et al. 2009; Zhou and
Freed 2009) and the transduction of recombinant cell-
penetrating proteins (Oct4, Sox2, Klf4, c-Myc) into mouse
(Zhou et al. 2009) or human (Kim et al. 2009) cells. In
addition, reprogramming with small molecules acting as
chromatin-modifying agents to replace the potentially
oncogenic reprogramming factors increased the repro-
gramming efﬁciency (Huangfu et al. 2008; Shi et al. 2008;
reviewed in Seiﬁnejad et al. 2010).
These new reprogramming technologies would enable
not only the generation of pluripotent cells for autologous
cell therapies, but would also allow for the application of
human iPS cells to speciﬁc issues in drug research and in
safety pharmacology or toxicology studies (reviewed in
Ebert and Svendsen 2010; Phillips and Crook 2010;
Rowntree and McNeish 2010), as well as for the analysis of
pathomechanisms of heritable diseases with ‘‘disease-spe-
ciﬁc’’ iPS cells (e.g. Dimos et al. 2008; Park et al. 2008;
Ebert et al. 2009; reviewed in Saha and Jaenisch 2009; Lee
and Studer 2010).
To overcome the limitations with respect to transgenesis
and gene targeting in hESCs (see ‘‘Embryonic stem (ES)
and embryonic germ (EG) cells’’), an alternative strategy
was proposed: reprogramming of human somatic cells
using ﬁve reprogramming factors (Oct4, Sox2, Klf4,
c-Myc, Nanog) in the presence of LIF yielded cells of a
human pluripotent state comparable to that of mouse ESCs
(Buecker et al. 2010). This state was found to facilitate
homologous recombination-mediated gene targeting also in
human pluripotent stem cells, but required the continued
expression of the ﬁve reprogramming factors. A pluripo-
tency stage of hiPSCs comparable to that of mESCs was
also found by Hanna et al. (2010) when reprogrammed
cells were cultured in the presence of a combination of the
ERK1/2 inhibitor PD0325901, the GSK3 inhibitor
CHIR99021 and LIF (Hanna et al. 2010).
However, there is a strong need to further analyse and
improve the reprogramming process. Several critical
parameters such as low reprogramming efﬁciencies (usu-
ally between 0.0001 and 0.1%; Maherali et al. 2007;
Wernig et al. 2007), only partial reprogramming (see Nagy
and Nagy 2010) and genetic instability of the generated
cells may be obstacles to the routine application of hiPSCs.
Speciﬁcally, the ‘‘epigenetic memory’’ of hiPSCs (Kim
et al. 2010b; Polo et al. 2010), the cell cycle status and the
genetic and epigenetic background of the somatic cells may
affect the reprogramming process (Jalving and Schepers
2009).
It was further shown that the cell type of origin and the
methods used for iPS cell generation can affect the
functional properties of iPS cells (Polo et al. 2010) and the
molecular characteristics deﬁning their pluripotent state
(Soldner et al. 2009). For example, viral integration of
transgenes modiﬁed the epigenetic state of the cells.
Accordingly, a higher similarity in the expression proﬁles
was found between ‘factor-free’ hiPS and hESCs, whereas
different hiPSC lines that had integrated DNA of the viral
vector used for reprogramming showed different molecular
patterns (Soldner et al. 2009). A ﬁrst study on gene
expression signatures of hESCs and hiPSCs disclosed
functional and developmental differences between ES- and
iPS-derived cells (Chin et al. 2009). However, a recent
detailed comparison of a panel of different hESC and
hiPSC lines revealed only subtle variations in chromatin
structure or gene expression patterns among individual
lines, but no consistent signatures that distinguish hiPS
from hESC lines when examined after extended culture
time (Guenther et al. 2010). Another study detected more
differences in gene expression and histone modiﬁcation
proﬁles between hES and hiPSCs generated by different
laboratories, suggesting that obviously methodical differ-
ences between separate studies rather than differences
between both pluripotent cell types have to be considered
(Newman and Cooper 2010).
However, other data may be also important to answer
the question, whether or not hESCs and hiPSCs resemble
similar pluripotent states. Murine iPS cells revealed a lower
efﬁciency, higher senescence and greater variability with
respect to their expansion and differentiation characteris-
tics than mESCs (Feng et al. 2010; Hu et al. 2010). It was
shown that a deﬁned maternally imprinted region on
chromosome 12 of miPS cells was important to deﬁne
pluripotency. Only iPS cell lines with normally activated
gene clusters were able to generate chimeras almost as
efﬁciently as mESCs, whereas cells with silenced clusters
were unable to give rise to chimeric animals (Stadtfeld
et al. 2010). In the future, the epigenetic status of the
chromosome 12 gene cluster eventually will allow the
identiﬁcation of iPS cell lines that have the full develop-
mental potential known from ESCs. It remains to be shown
whether similar ‘‘epigenetic hot spots’’ also exist in human
iPS cells (Dolgin 2010).
Moreover, a close correlation between pluripotency and
tumourigenicity as well as remarkable similarities between
the reprogramming process leading to induced pluripoten-
cy and oncogenic transformation may have also a critical
impact on toxicity studies (reviewed in Knoepﬂer 2009;
Krizhanovsky and Lowe 2009; Wobus 2010). The fol-
lowing aspects may be important with respect to potential
tumourigenesis of reprogrammed iPS cells: (1) the repro-
gramming factors are involved in tumour initiation (Jalving
and Schepers 2009), (2) the suppression of the p53 pathway
in pluripotent stem cells necessary for reprogramming may
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2009), (3) high telomerase activity required for unlimited
proliferation is a property of both pluripotent stem and
tumour cells (Marion et al. 2009; Vaziri et al. 2010;
Zalzman et al. 2010) and (4) the in vitro culture required to
establish iPS cells may induce chromosomal aberrations
(Mayshar et al. 2010) and, possibly, epigenetic changes.
Nevertheless, reprogramming by induced pluripotency
offers exciting perspectives for regenerative medicine and
pathogenesis research, and also for toxicity testing and
drug research (see Nishikawa et al. 2008). Speciﬁcally,
both human ES and iPS cells have been proposed as in
vitro test systems for pharmaco-toxicological studies
(Sartipy et al. 2006; Caspi et al. 2009; Ebert and Svendsen
2010; Trosko and Chang 2010) and companies have started
to establish new strategies based on hPSCs to provide new
models for drug safety testing (Baker 2010). Examples of
these applications and ﬁrst results will be presented in the
next sections.
Mutagenicity/genotoxicity studies using EC,
EG and ES cells
Mutagenic substances induce gene mutations, but also
structural and numerical chromosomal aberrations. Geno-
toxic factors are capable of damaging DNA, but they can
also affect cellular components that regulate the ﬁdelity of
the genome, such as the spindle apparatus, topoisomerases,
DNA repair systems and DNA polymerases. These effects
may directly or indirectly involve the genetic material and
result in developmental perturbations, abnormal embryo-
genesis and malformations. A combination of mutagenicity
tests has been designed to detect potential consequences of
exposure to chemicals. These include analyses of major
endpoints of genetic damage associated with human dis-
eases, such as gene mutations as well as structural and
numerical chromosomal aberrations. Studies in the past
clearly documented that no single assay can detect all
genotoxic or mutagenic substances. Therefore, a battery of
appropriate in vitro and in vivo tests to detect mutagenicity
was established (reviewed in Eastmond et al. 2009).
Genotoxic effects on germ cells are of crucial importance
because gene mutations or chromosome damage may be
transferred to the offspring and future generations. Strate-
gies for in vivo germ cell testing include the mammalian
spermatogonial, chromosome aberration, dominant lethal
(Russell and Russell 1954; Ehling 1974), speciﬁc locus
(Ehling et al. 1978; Russell et al. 1981) and mouse heritable
translocation assays (see Eastmond et al. 2009). These tests
usually require large numbers of several generations of
animals, which are time-consuming and expensive. There-
fore, researchers have long been interested in developing
alternative in vitro methods. Most of these assays were
based on bacterial reverse mutation tests or on somatic cells,
such as primary and permanent cell lines including trans-
genic reporter cell lines, but did not rely on embryonic or
germ cells (Brown et al. 1995; reviewed in Spielmann 1998;
Spielmann 2005).
In the 1990s, pluripotent embryonic carcinoma (EC) and
embryonic stem (ES) cells offered for the ﬁrst time the
opportunity to analyse the mutagenic or genotoxic and
cytotoxic effects of chemical mutagens on embryonic cells
in vitro (reviewed in Rohwedel et al. 2001). First studies
that aimed at determining the mutagenic effects of the
alkylating substancesENU (N-ethyl-N-nitrosourea), MNNG
(N-methyl-N’-nitro-N-nitrosoguanidine) and the DNA
crosslinking and alkylating agent mitomycin C(MMC)
were performed on undifferentiated P19 EC cells. When
compared to EPI-7 cells, an epithelial derivative of P19
cells, the undifferentiated P19 EC cells were found to be
less sensitive with respect to the induction of 6-thiogua-
nidine resistance (6-TG
r), suggesting a higher or more
efﬁcient DNA repair capacity of undifferentiated in com-
parison with differentiated cells. But it has been also dis-
cussed that EC cells may be less sensitive because of their
malignant status, which makes them more resistant to
anticancer drugs (Sehlmeyer and Wobus 1994; Sehlmeyer
and Wobus 1995; Sehlmeyer et al. 1996a).
Similarly, when the sister chromatid exchange (SCE)
frequency was investigated as an endpoint of mutagenic
effects (Vogel 1993), it was found that EC and ES cells
reacted with the same or even lower sensitivity to ENU
than differentiated cells (Bremer and Vogel 1999). A
comparison of SCE frequencies of mouse EG cells and
ﬁbroblasts revealed a higher sensitivity of EG cells after
treatment with MMS (methylmethane sulphonate), HU
(hydroxyurea), MNU (methyl-nitrosourea), ENU and
MMC (Klemm et al. 2001a; Klemm et al. 2001b). Based on
these data, a biostatistical prediction model for genotoxi-
city on EG cells in vitro was established, which showed a
correct classiﬁcation for 5 genotoxic and three non-geno-
toxic test chemicals (Klemm et al. 2001a). In addition,
numerous in vivo studies demonstrated that germ cells of
different stages reacted differently to mutagenic com-
pounds depending on the speciﬁc substance tested (Ehling
1974; Favor et al. 1990). But, it should be also considered
that SCEs, chromosome aberrations and point mutations
are different endpoints of mutagenesis that may consider-
ably vary for speciﬁc mutagens, and different primary
lesions may be involved (Sonoda et al. 1999).
Later on, transgenic ESC lines containing speciﬁc ‘loss-
of-function’ mutations in genes regulating DNA repair or
drug resistance metabolism have been used to analyse
mechanisms of mutagenicity and genotoxicity. Such
ESC lines were deﬁcient for ERCC1 (‘excision repair
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cells’), a gene involved in nucleotide excision repair (Van
Sloun et al. 1999), for Msh2 and Msh3 involved in DNA
mismatch repair (Abuin et al. 2000), for the gene encoding
the ‘multidrug resistance-associated protein’ (MRP, Lorico
et al. 1996) or the tumour suppressor p53 (Donehower et al.
1992). Using p53-deﬁcient ESCs, effects of electromag-
netic ﬁelds (EMF) have been analysed. Exposure of p53-
deﬁcient ESCs to EMF resulted in altered transcript levels,
whereas wild-type ESCs that were treated in a similar way
did not show these responses (Czyz et al. 2004a; Czyz et al.
2004b).
Also, ‘gain-of-function’ approaches have been applied
to cytotoxicity studies with ESCs. Over-expression of the
heat shock protein HSP27 in ESCs demonstrated that
HSP27 is involved in protection against metal toxicity (Wu
and Welsh 1996).
In summary, pluripotent stem cells including genetically
altered EC or ES cell lines were found to be useful models
to analyse genotoxic/mutagenic effects of drugs and
xenobiotics. These cellular systems may be more relevant
for germ cells or early embryos than for somatic cells,
because ES and somatic cells differ in their mutation fre-
quencies. Mutations were induced less frequently in ESCs
than in somatic cells; however, it has to be noted that
extended culture of mESCs may result in the accumulation
of mutations (uniparental deﬁciency rather than loss of
heterozygosity; Cervantes et al. 2002).
Embryotoxicity tests using pluripotent stem cells
The need to establish reliable in vitro tests
for embryotoxicity of chemicals
The effects of chemicals or drugs on germ cells or early
embryos may lead to infertility or impaired development of
pre-implantation embryos and result in embryotoxic or
teratogenic effects in the progeny (for review see Spiel-
mann 2005; Krtolica et al. 2009). A system of versatile
tests for reproductive toxicity had been established to
systematically screen for such hazards present in the daily
life, including chemical compounds that are components of
drugs and pharmaceuticals. Such test systems are required
for reproductive toxicological analyses and are part of
governmental regulations. The OECD Guidelines for test-
ing industrial and agrochemicals stipulate extensive
screening and multi-generation studies including tests for
teratological, reproductive and developmental effects,
neurotoxicity, oestrogenic and androgenic properties and
include extensive one- and two-generation reproductive
toxicity studies (reviewed in Spielmann 2009). Chemicals
that are parts of drugs have to be investigated in segment
studies covering combined fertility and embryotoxicity
(Segment 1), teratology (Segment 2) and pre- and postnatal
development (Segment 3) studies (for overview see Seiler
et al. 2004). However, these in vivo tests are time-con-
suming, laborious and expensive and, speciﬁcally, require
the use of high numbers of laboratory animals.
Therefore, alternative in vitro screening methods have
been developed to detect potential hazardous effects of
chemicals or drugs on embryonic development, but until
now, these test systems have not been accepted for regu-
latory purposes. These assays include the frog embryo
teratogenesis assay (FETAX) on xenopus (Bantle et al.
1990), the chicken embryo toxicity screening test (CHEST)
on chicken embryos (Jelinek et al. 1985; Boehn et al.
2009), the micromass (MM) assay using mouse embryonic
mesenchymal cells (reviewed in Flint 1993; Brown et al.
1995; Spielmann 2005), and the mammalian whole embryo
culture (WEC) assay using mouse (e.g. Sadler et al. 1982)
or rat (Schmidt 1985; reviewed in Cockroft and Steele
1987). In addition, mammalian cells have been introduced
as in vitro test systems for cytotoxicity, embryotoxicity or
teratogenicity screening (Kimmel et al. 1982; Schwetz
et al. 1991). Whereas the MM test and the WEC assay
(based on in vitro culture of mammalian embryos) were
validated and proposed as promising systems for screening
of embryotoxic compounds, the CHEST assay was unable
to distinguish between general and developmental toxicity,
and the FETAX test has not been sufﬁciently validated
(reviewed in Spielmann 2005). The most important draw-
back of all these assays is that they rely on somatic cells
that not entirely reﬂect the reaction of embryonic cells to
toxic compounds.
Early studies analysing cytotoxic effects of chemicals
on murine EC, ES and EG cells
Tests for embryotoxicity include the analysis of toxic
effects of drugs or environmental factors on embryonic
cells or on cells of (early) embryonic developmental stages,
whereas cytotoxicity assays also measure drug-induced
alterations of metabolic pathways or structural integrity of
the cells, which may or may not be directly related to cell
death. Both cytotoxicity and embryotoxicity assays have
been established with pluripotent stem cells.
Studies to determine cytotoxic effects of chemical
compounds based on the colorimetric MTT test for cellular
growth and survival (Mosmann 1983) were performed with
murine EC (Atkinson et al. 1989), ES (Laschinski et al.
1991) and EG (Klemm et al. 2001b; Klemm et al. 2001a)
cells. Undifferentiated mEC and mEG cells showed a
higher sensitivity to selected embryotoxic agents when
compared to mouse ﬁbroblasts. Whereas in the MTT test,
cell survival is determined indirectly by measuring
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chemical compounds, the cloning efﬁciency test relies on
the reproductive integrity of the cells and, therefore, should
more directly reﬂect cytotoxic effects of test compounds.
Consequently, cytotoxicity assays based on the reproduc-
tive integrity of cells (=clonogenicity) after application of
mutagenic chemicals (ENU, MMC and MNNG) were
established by using murine EC, EG and ES cells: a higher
sensitivity of mEG cells in comparison with differentiated
EPI-7 cells was detected, whereas both mEC cells and
mESCs were less sensitive (Sehlmeyer et al. 1996b).
Embryotoxicity studies using mESCs
To overcome the limitations of cytotoxicity assays for the
determination of embryotoxic effects of drugs or xenobi-
otics in vitro, the ESC-derived embryoid body (EB) model
was introduced (Wobus et al. 1988; Wobus et al. 1991;
Wobus et al. 1994a). ESCs differentiated in EBs for
5–7 days develop in vitro into progenitor cells of all three
primary lineages of ectoderm, mesoderm and endoderm
(reviewed in Wobus and Boheler 2005). The rationale of
the EB model was that early developmental processes
simulated by EB differentiation would be affected by
treatment of undifferentiated PSCs with toxic substances
and, as a consequence, speciﬁc differentiation processes
would be inhibited, induced or accelerated.
At ﬁrst, the well-known teratogen all-trans retinoic acid
(RA) was applied at different concentrations and at speciﬁc
time intervals of EB differentiation. It was found that RA
affected the differentiation of mEC (Strickland and
Mahdavi 1978; Edwards and McBurney 1983; Jones-
Villeneuve et al. 1983) and mES (Strubing et al. 1995;
Dani et al. 1997; Drab et al. 1997; Wobus et al. 1997;
reviewed in Rohwedel et al. 1999; Rohwedel et al. 2001)
cells in a concentration- and time-dependent manner. There
is evidence that in vivo RA acts as morphogen forming a
concentration-dependent gradient along embryonic axes,
thus affecting the antero-posterior patterning of the body
axis and the limbs (Kessel and Gruss 1991).
Such concentration- and stage-speciﬁc effects were also
observed with mESCs in vitro. For example, high con-
centrations of RA applied to mESCs during early EB dif-
ferentiation (day 0–2) revealed increased neural-speciﬁc
transcript levels and signiﬁcantly induced neuronal differ-
entiation (Fraichard et al. 1995; Strubing et al. 1995),
whereas RA application at lower concentrations applied
between day 2 and 5 induced mesodermal, speciﬁcally
skeletal muscle and partially cardiac differentiation (Wo-
bus et al. 1994b). This is in line with developmental pro-
cesses in the EB, where maximum expression levels of
Brachyury (T) and expression of genes associated with
dorsal mesoderm speciﬁcation are observed at around day
3 of EB formation (Wobus et al. 1994b; Dani et al. 1997).
Cardiac and vascular smooth muscle cells both originating
(at least partially) from lateral plate mesoderm were
induced by RA when applied at days 5–7 and 7–11,
respectively (Wobus et al. 1994b; Drab et al. 1997; Wobus
et al. 1997; Fig. 1). Obviously, the speciﬁc temporal
response of the different cell types within the EB to RA
correlated with RA receptor gene expression (reviewed in
Rohwedel et al. 1999). These early studies provided the
basis for the subsequent establishment of the so-called
Embryonic Stem Cell Test (EST, see ‘‘Embryonic stem cell
test (EST) with mESCs’’).
Similar distinct time- and development-speciﬁc effects
of chemical compounds on ESC differentiation were also
detected with lithium chloride (Schmidt et al. 2001) and
suramin, a naphthylamine derivative of urea (Wiese et al.
2009). Lithium chloride applied to ESC-derived EBs at
high concentration between days 5 and 15 caused redu-
ced cardiac-a-MHC and skeletal muscle-speciﬁc MyoD,
but slightly increased neural-speciﬁc synaptophysin and
NFM transcript levels and led to the inhibition of car-
diac and myogenic differentiation (Schmidt et al. 2001).
High concentration of suramin between day 5 and 7
enhanced cardiac differentiation with speciﬁc induction of
Fig. 1 Stage-speciﬁc effects of all-trans retinoic acid (RA)o n
embryoid body (EB) differentiation of murine ES cells. Shown are
scanning electron micrographs of 2d-, 5d- and 7d-EBs. ESC-derived
EBs were treated with different RA concentrations (10
-7,1 0
-8,1 0
-9
M) during deﬁned cultivation periods (0–2, 2–5,[5 days). The
different effects of RA on neuronal cell (NC), skeletal muscle cell
(SMC), adipocyte (APC), cardiomyocyte (CMC) and vascular smooth
muscle cell (VSMC) differentiation is demonstrated by inducing (?,
??, ???), inhibiting (-, --)o rn o( ±) effects. Bars = 50 mm
(original data from Wobus et al. 1994b; Strubing et al. 1995; Dani
et al. 1997; Drab et al. 1997; see also Rohwedel et al. 1999)
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123pacemaker-like cells, but inhibited neuronal, skeletal
muscle and deﬁnitive endoderm differentiation (Wiese
et al. 2009).
These studies demonstrated that the morphological
evaluation of EB outgrowths after treatment with certain
chemical compounds is only partially suitable to assess
developmental toxicity since lineage-speciﬁc develop-
mental effects are not perfectly mirrored. The data further
showed that the developmental stage, at which substances
were applied (undifferentiated ESCs vs. differentiating EBs),
may affect the embryotoxic effects and that analysis of
transcript levels of various lineage-speciﬁc genes may be a
better indicator for developmental toxicity (Schmidt et al.
2001; reviewed in Rohwedel et al. 1999).
In addition to the well-established EST (see ‘‘Embryonic
stem cell test (EST) with mESCs’’), in vitro models based
on differentiation of mESCs are generally accepted sys-
tems to test potential toxic effects of chemical compounds.
For example, Lim and co-workers recently tested the
cytotoxic effects of phthalate esters on mESC-derived
neural progenitors and determined the neurotoxicity of
mono-(2-ethylhexyl) phthalate, a degradation product of
the commonly used commercial plasticizer for polyvinyl-
chloride plastics (Lim et al. 2009). Meamar et al. (2010)
found that 3,4-methylenedioxymetamphetamine (MDMA,
ecstasy) inhibited neural and cardiac differentiation of
murine ESCs at micromolar concentrations (Meamar et al.
2010).
In conclusion, the suitability of murine ESCs for toxi-
cological analyses has been demonstrated in a broad range
of studies on potential embryotoxic effects of speciﬁc
compounds. However, the integration of such test systems
into regulatory framework will require the standardization
and validation of developmental toxicity tests using ESCs.
Embryonic stem cell test (EST) with mESCs
The mouse embryonic stem cell test (mEST) established by
Spielmann and co-workers (Spielmann et al. 1997) is based
on two assumptions. First, in vitro tests of basal cytotox-
icity are sufﬁciently predictive for the rodent in vivo LD50
assay (Ekwall 1999; Spielmann et al. 1999) and, second,
ESCs show alterations in their in vitro differentiation pat-
tern when exposed to embryotoxic chemicals during EB
differentiation (Wobus et al. 1988; Wobus et al. 1994b).
The validated EST was proposed in 2002 as a scientiﬁcally
validated in vitro method for detecting embryotoxicity (
http://ecvam.jrc.it; see Spielmann 1998) and is based on the
assessment of three toxicological endpoints and the com-
parison of data from three independent assays (see Fig. 2):
1. Morphological analysis of beating cardiomyocytes in
EB outgrowths derived from mouse ESCs (line D3,
Doetschman et al. 1985) and cultured in the presence
of the test substance.
2. Cytotoxic effects on undifferentiated D3 ESCs.
3. Cytotoxic effects on NIH 3T3 ﬁbroblasts following
application of test substances.
The test comprises the analysis of beating clusters in
differentiating EBs (plated into single wells of microwell
plates) and the determination of those concentrations of the
test substance at which cardiac differentiation is inhibited
by 50% (ID50). The cytotoxic effects on ES and 3T3 cells
were estimated by determining those concentrations of the
test substance at which proliferation was inhibited by 50%
(IC50 D3 and IC50 3T3, respectively). On the basis of these
data, concentration–response curves were generated and a
biostatistical prediction model was established to assign the
test compounds to three classes of embryotoxicity: non-
embryotoxic, weakly embryotoxic and strongly embryo-
toxic (Genschow et al. 2002, 2004; Seiler et al. 2006). The
EST was validated by using a set of 20 test compounds of
known in vivo embryotoxicity. The embryotoxic potential
of the test compounds was predicted with about 78%
accuracy for non-embryotoxic and weakly embryotoxic
compounds and 100% for strongly embryotoxic chemicals
(Genschow et al. 2002, 2004). Together with the MM and
rat WEC test, the mEST would be ready to be accepted by
the regulatory commissions (Balls and Hellsten 2002);
however, the Scientiﬁc Advisory Committee (ESAC) of the
European Centre for the Validation of Alternative Methods
(ECVAM) recognized that the three methods were still not
qualiﬁed to replace the animal experiments stipulated in the
present integrated test strategies (Spielmann 2009). For
example, it was argued with respect to the mEST that data
Endpoint 1:
inhibition of differentiation
ES cells
Endpoint 2:
cytotoxic effects
ES cells
Endpoint 3:
cytotoxic effects
3T3 cells
Endpoints: assessment from concentration response curves
1. inhibition of differentiation in ES cells ID50
2. cytotoxic effects on ES cells IC50D3
3. cytotoxic effects on 3T3 cells IC503T3
Fig. 2 The embryonic stem cell test (EST) established for mESCs by
Spielmann and co-workers. The EST comprises three parameters, the
differentiation of mES cells (endpoint 1), cytotoxic effects on ES (D3)
cells (endpoint 2) and on NIH 3T3 ﬁbroblasts (endpoint 3). On the
basis of these data, concentration response curves were established
and the prediction for embryotoxic effects of compounds calculated
(according to Seiler et al. 2006; see text for further information)
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123on only 20 chemicals were not sufﬁcient to make ﬁnal
decisions on embryotoxicity. A new Integrated Project
ReProTect was initiated within the European Union
Framework Program 6, in which a new set of 13 non-
classiﬁed chemicals was studied (Hareng et al. 2005).
Since these test chemicals were not correctly classiﬁed by
the EST, modiﬁcations and new endpoints were recom-
mended for the EST (see Spielmann 2009).
Indeed, the primary (validated) mEST had several lim-
itations. Since ESCs were differentiated as EBs in ‘‘hang-
ing drops’’, the test was (1) laborious and (2) time-
consuming. (3) The substances were applied over the
whole process of differentiation, (4) cardiac differentiation
(formation of beating cardiomyocytes) was the only end-
point of the developmental analysis, and (5) no molecular
parameters were considered (Schmidt et al. 2001; Piersma
2004; Seiler et al. 2006). It was recommended to include
further endpoints, such as additional differentiation mark-
ers of ectoderm, mesoderm and endoderm lineages and the
analysis of tissue-speciﬁc gene expression.
Based on previous studies that demonstrated lineage-
dependent effects of RA on ESC differentiation (Wobus
et al. 1994b) and the application of reporter gene constructs
controlled by cardiac-speciﬁc promoters (Wobus et al.
1997; Kolossov et al. 1998), a battery of transgenic murine
ESC lines expressing reporter genes controlled by different
lineage-speciﬁc promoters was proposed as a test system
for embryotoxicity (Rohwedel et al. 2001).
In addition, several studies that aimed on improving the
EST by inclusion of new morphological and molecular
endpoints were performed during the last years and
methodical improvements were achieved. For example,
serum replacement (SR) was substituted for foetal calf
serum (FCS), and chemically deﬁned media (CDM) were
used in the EST (Seiler et al. 2006). Furthermore, reporter
gene assays for developmental toxicity, speciﬁcally for
cardiac toxicity (Bremer et al. 2001), have been included
into the EST. The cardiac markers a-myosin heavy chain
(MHC) and a-actinin were used instead of microscopical
observation of beating EBs to determine cardiac differen-
tiation after application of the test substances, and quanti-
ﬁcation of marker gene expression by FACS was
performed after labelling of cells (Seiler et al. 2004; Seiler
et al. 2006). The FACS-based EST (called ‘‘Molecular
FACS-EST’’) was successfully validated for assessing
developmental toxicity (Buesen et al. 2009). While the
‘‘Molecular FACS-EST’’ showed the same sensitivity as
the validated EST, the test duration was reduced and the
test allowed for a more rapid and reproducible screening
and for predicting developmental toxicity in vivo on the
basis of in vitro data. Almost identical ID50 values were
obtained for ten representative compounds of the three
classes, indicating that values from FACS analyses can
serve as new ‘‘toxicological endpoint’’ of the EST.
Furthermore, the inclusion of additional endpoints of
differentiation, speciﬁcally of the neural lineage, was
requested by researchers and authorities (Spielmann et al.
2006). The rationale of using such systems is to correctly
classify substances that were not identiﬁed as embryotoxic
in the conventional EST. The inclusion of parameters for
neuronal differentiation into the mEST allowed, for
example, the classiﬁcation of methylmercury as a highly
embryotoxic substance in accordance with in vivo data,
whereas the conventional EST failed to correctly classify
this compound (Stummann et al. 2007). To further increase
the number of molecular markers as endpoints of embry-
otoxicity testing, real-time Taqman RT-PCR analyses have
been adopted for the EST in a pilot study (zur Nieden et al.
2004).
Metabolic activation of speciﬁc chemical compounds
was recognized as another potential factor to affect the
experimental outcome of the EST and correct classiﬁcation
of test substances (Verwei et al. 2006). However, the S9
mix usually applied for metabolic activation of chemicals
is toxic for ESCs and respective experiments have failed so
far. Therefore, the consortium of the ReProTect project
recommended other test systems, such as the Ames test, to
analyse potential toxicity of compounds that require met-
abolic activation (Marx-Stoelting et al. 2009).
Peters and co-workers determined the ‘‘Relative Em-
bryotoxic Potential’’ (REP) by using a modiﬁed EST
screening system (Peters et al. 2008). In this study, 12
compounds were investigated in a modiﬁed EST performed
in 96-well plates. Test substances were applied at day 3 of
culture for 10 days, and the essay did not involve the
preparation of EBs. This ‘‘Newly Revised High Through-
put EST’’ allowed the analysis of a higher number of
substances, while less manual work was required, and
yielded data comparable to those obtained with the con-
ventional EST.
At present, the EST is the only well-established in vitro
test for developmental toxicity based on mammalian cells
(Bremer and Hartung 2004). Present efforts to improve the
EST are directed towards the application of additional
lineage-speciﬁc markers to deﬁne additional toxicological
endpoints. In addition to cardiac markers, markers of
neuronal, bone and cartilage development are included.
However, this will prolong the test duration from 7 or
10–30 or 32 days (Marx-Stoelting et al. 2009). In the
future, novel molecular endpoints and reporter-based sys-
tems have to be included into the EST (see Rohwedel et al.
2001; Marx-Stoelting et al. 2009; Spielmann 2009). Such
improvements would also be needed for the establishment
of EST-like tests with human ESCs.
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123Screening of cytotoxic and embryotoxic effects using
hESCs
The development of hESC-based in vitro systems for
testing embryotoxicity of chemical compounds would be a
signiﬁcant progress. The use of hESCs would enhance the
predictivity of in vitro assays and avoid problems associ-
ated with the interpretation of results from animal-based
assays in a human context. For example, species-speciﬁc
differences between mouse and human preimplantation
development, such as in DNA methylation, DNA repair
and expression of genes involved in drug metabolism may
hamper the correct interpretation of animal studies for
human beings (reviewed in Krtolica et al. 2009). The use of
hESC-based test systems could avoid incorrect classiﬁca-
tion of chemicals due to inter-species variations and, con-
sequently, would increase the safety of consumers and
patients.
The question whether hESCs would be a suitable
model for analysing developmental toxicity was investi-
gated in several recent proof-of-concept studies (for
overview see Table 3). In some of these studies, potential
toxic effects of agents and noxes (such as certain chemical
compounds, radiation, ethanol or cigarette smoke) on the
viability and integrity of hESCs were investigated (Adler
et al. 2008a; Zdravkovic et al. 2008; Krishnamoorthy
et al. 2010; Lin et al. 2010; West et al. 2010; Wilson et al.
2010). This kind of studies may allow conclusions on the
effects of certain hazards on the preimplantation embryo
in vivo. In a panel of further studies, effects of well-
known embryotoxic agents on the induction and pro-
gression of hESC differentiation were examined and
endpoints suitable for the detection of embryotoxic effects
on early stages of hESC differentiation were proposed
(Adler et al. 2008b; Mehta et al. 2008; Flora and Mehta
2009; Stummann et al. 2009b). It is supposed that this
kind of investigations might have implications for
assessing potential risks even during later stages of
embryonic and foetal development.
For example, Adler and co-workers provided proof-of-
concept that hESCs are a relevant in vitro model for
developmental toxicity testing. In one study, the cytotoxic
effects of well-known embryotoxicants [all-trans retinoic
acid (ATRA), 13-cis RA (13CRA), valproic acid (VA) and
dimethylsulfoxide (DMSO)] on hESCs, hESC-derived
progenitors and human foreskin ﬁbroblasts were investi-
gated (Adler et al. 2008a). As observed in the respective
murine cells, ATRA and 13CRA had a stronger cytotoxic
Table 3 Published developmental toxicology studies involving hESCs- and/or hESC-derived cells
Study hESC lines Noxes tested Endpoints used/identiﬁed
Adler et al. (2008a) SA002; SA002.5 Known developmental toxicants (VPA,
ATRA, 13-CRA); DMSO
hES cell viability (ATP content, resazurin reduction)
Adler et al. (2008b) H1 Known developmental toxicant (RA) hES cell viability (resazurin reduction); mRNA
levels of genes coding for stemness markers (Oct4,
hTert); mRNA levels of genes coding for
mesodermal and cardiac differentiation markers
(Brachury; GATA-4, Nkx 2.5; MyH6)

Flora et al. (2009) ReliCell hES1 Arsenic (potential reversal of arsenic effects
by MiADSA were also investigated)
mRNA levels of stemness markers; mRNA levels of
genes representative of the three germ layers
Krishnamoorthy
et al. (2010)
H9; Bg02; abBG02 Ethanol at low concentrations CHRNA5 gene expression level
Lin et al. (2010) H9 Smoke from conventional and
harm-reduced cigarettes
hESC morphology; hESC apoptosis
Metha et al. (2008) ReliCell hES1 Strong (busulfan; hydroxyurea), weak
(caffeine, indomyacin) and non-
embryotoxic (penicillin, saccharin)
compounds
mRNA levels of genes coding for stemness markers;
expression levels of genes representative of the
three germ layers
Stummann et al.
(2009)
H1 Methylmercury (MeHg) mRNA levels of genes coding for neural lineage
markers in differentiating cells (NCAM; NeuroD;
MAP2)
West et al. (2010) H9 Several drugs with known teratogenic
effects in human
Abundance of certain small molecules (metabolites)
as detected by mass spectrometry
Wilson et al. (2010)H 9 c-radiation (0.4–4 Gy) hESC viability; global gene expression changes in
hESCs
Zdravkovic et al.
(2008)
H7; H9 Nicotine exposure Morphology and adhesion of hESCs; expression of
stemness markers; hESC apoptosis
More details are given in the text.
 Effects of RA on cardiac differentiation of hESCs were not tested
Arch Toxicol (2011) 85:79–117 91
123effect on pluripotent stem cells than on ﬁbroblasts, while
mesenchymal progenitors derived from hESCs showed the
highest sensitivity to both compounds. Interestingly, while
both substances revealed comparable cytotoxic effects on
human ESCs in this study, only ATRA but not 13CRA
were shown to be cytotoxic in mouse ESCs in previous
analyses, indicating the necessity of developing hESC-
based assays for the assessment of human-speciﬁc devel-
opmental toxicity. In a second study, Adler and co-workers
arranged the test system according to the EST, but used
human instead of mouse ESCs (Adler et al. 2008b). Using
two well-known developmental toxicants [5-ﬂuorouracil
(5-FU) and ATRA], cytotoxic effects similar to those
previously observed in mouse systems were observed in
hESCs and human ﬁbroblasts. However, testing for
potential cytotoxic effects on pluripotent stem cells is not
sufﬁcient to detect developmental toxicity of chemicals
that affect developmental processes (reviewed in Rohwedel
et al. 2001). Since the conventional EST based on mESCs
depends on the microscopical observation and counting of
beating areas after ESC differentiation and therefore car-
diac differentiation is not precisely determined, the authors
suggested several other potential endpoints for the analysis
of toxic effects on differentiating hESCs. For example,
markers of undifferentiated cells such as Oct4, hTert
(human telomerase reverse transcriptase) and Dusp6 (dual
speciﬁcity phosphatase 6) were shown to decrease reliably
during early differentiation of hESCs, while Brachyury and
GATA-4, markers of mesoderm and early cardiogenesis,
were found to be suitable to monitor cardiac differentia-
tion. The authors suggested that these markers may have
the potential to serve as endpoints for developmental tox-
icity studies using a humanized EST (Adler et al. 2008b).
In a recent study, the effects of methylmercury (MeHg, a
well-known developmental toxicant) on neural differenti-
ation of hESCs were investigated (Stummann et al. 2009b).
MeHg caused a marked decrease in mRNA levels of neural
lineage-speciﬁc genes expressed in neural progenitors
when added to hESCs at sub-cytotoxic levels from day 0 to
day 12 of neural differentiation. In contrast, when added at
later stages of neural differentiation (day 21–38), the effect
of MeHg on mRNA levels of genes expressed in more
mature neural cells was much less pronounced. These
results are different to those obtained in studies with mouse
ESCs (Stummann et al. 2007), in which MeHg exerted its
repressive effect on neural differentiation probably rather
by inhibition of maturation of neural precursor cells. Thus,
there are possible species-speciﬁc differences in the
mechanism of MeHg toxicity between man and rodents,
which underline the need to establish human cell-based test
systems for determining developmental toxicity in man.
While some studies using hESCs as model for early
developmental toxicity are based on investigation of subtle
differences in mRNA levels of lineage-speciﬁc genes, in
one study changes in the abundance of small molecules in
hESCs were investigated subsequent to exposure of cells to
known developmental toxicants (West et al. 2010). Using a
panel of well-deﬁned human teratogens, biomarkers were
identiﬁed that may be suited to predict developmental
toxicity. For example, changes in the levels of asymmetric
dimethylarginine (ADMA) and arginine were of some
predictive value for the qualiﬁcation of substances as ter-
atogens or non-teratogens. Unfortunately, this study suffers
from the lack of (non-hES) reference cells. Moreover, it
remains to be determined whether changes in metabolite
levels are also a reliable parameter to determine toxic
effects on differentiating cells.
In another study, a cytotoxicity test system based on
feeder-free hESCs and hESC-derived EBs was established,
with human foreskin ﬁbroblasts as reference cells (Mehta
et al. 2008). Embryotoxic effects of several compounds
(busulfan, hydroxyurea, indomethacin, caffeine, penicillin
and saccharin) were tested using a cell proliferation assay.
Developmental toxicity was assessed by quantitative RT-
PCR analysis of alterations in transcript proﬁles of lineage-
speciﬁc marker genes. The authors demonstrated proof-of-
concept that hESCs can serve as a model to test embryo-
toxic effects of chemicals and that alterations in transcript
levels of early lineage-speciﬁc markers are, to a certain
degree, correlated with known embryotoxic effects caused
by drugs or chemicals. More recently, the same group
provided data on the reversal of arsenic-induced develop-
mental toxicity by monoisoamyl dimercaptosuccinic acid
(MiADMSA) in a human EB model (Flora and Mehta
2009). While arsenic at non-cytotoxic concentrations of
0.1 ng/ml signiﬁcantly down-regulated expression of genes
representative for all germ layers, this effect was abrogated
by MiADMSA. Interestingly, these results were mirrored
by the outcome of in vivo studies using pregnant Wister
rats in which MiADMSA treatment reduced arsenic-
induced visceral and skeletal defects in the offspring. Thus,
the human EB model may be not only a suitable model to
study effects of embryotoxic compounds, but may also be
useful to identify drugs that can revert or prevent the
effects of such compounds.
Future challenges and perspectives for embryotoxicity
studies using pluripotent stem cells
The recent developments in the improvement of the EST
have underlined our previous requests to implement new
strategies for embryotoxicity testing by using ESCs (1) by
the analysis of tissue-speciﬁc genes via reporter gene
expression, (2) automated high-throughput screening for
changes in gene and protein expression patterns using
microchip arrays for transcriptome and proteome analyses
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123and (3) the application of human ESCs (see Rohwedel et al.
2001).
Until now, some progress has been made in the deter-
mination of endpoints suitable for determination of
embryotoxicity in differentiating hESCs, and proof-of-
concept was provided that hESC-based in vitro systems
may be useful to predict human-speciﬁc developmental
toxicity. However, there are numerous problems to be
solved before hESC-based assays can be implemented into
routine procedures for developmental toxicity testing of
drugs and chemicals. These include (1) the establishment
of reliable and reproducible differentiation procedures that
can be performed in a high-throughput format. (2) The
predictivity, sensitivity and speciﬁcity of the respective test
systems have still to be shown for a wider panel of drugs
and chemicals. So far, only few substances have been
tested in the different approaches. (3) Furthermore, hESC-
based systems may have the capacity to predict human-
speciﬁc embryotoxic effects that cannot be measured with
mouse cell systems due to species-speciﬁc differences.
However, the superiority of hESC-based systems over
existing in vitro tests for developmental toxicity has still to
be shown, e.g. by performing thorough comparisons
between established and hESC-based tests. In this context,
the use of different hESC lines would be advantageous. (iv)
Most importantly, drugs that were identiﬁed as embryo-
toxic only in late-stage animal toxicity studies or even after
drug approval need to be tested in hESC-based in vitro
models. Positive test results would be encouraging and
would further stimulate the development in this ﬁeld. In
addition, it was discussed that the application of hiPSCs in
embryotoxicity testing might be a promising tool as well
(Heng et al. 2009). However, future work has to show
whether hiPSCs will be applicable and offer advantages
over hESCs in the ﬁeld of developmental toxicology.
The potential of human pluripotent stem cell-derived
cardiomyocytes in cardiac safety pharmacology
and cardiotoxicity research
Requirements for safe and reliable in vitro models
in cardiotoxicology
Cardiotoxicity is one of the leading reasons for drug
attrition and is therefore critical for development and safety
testing of new drugs. Within the process of drug develop-
ment, all new compounds must be evaluated for sub-clin-
ical cardiotoxicity (i.e. alterations of contractility,
induction of arrhythmias, alteration on blood pressure and
ischaemia) as potentially life-threatening events or effects
that may result in cardiac morbidity (Stummann et al.
2009a). The major clinical manifestation of cardiotoxic
effects includes drug-induced arrhythmias, contractility
toxicity, ischaemia toxicity, secondary cardiotoxicity and
valve toxicity. The requests for cardiotoxicity testing by
the regulatory authorities are key requirements in phar-
maceutical regulatory framework and are deﬁned in the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use (ICH) S4 guidelines and the ‘‘Guideline on
Repeated Dose Toxicity’’ of the EMEA.
Duringrecentyears,aconsiderablenumberofdrugswere
withdrawn from the market due to unforeseen cardiotoxic
sideeffects,andcardiotoxicityisoneofthemajorreasonsfor
late-stage attrition of drugcandidates. The earlydetection of
fatal side effects of new drugs can therefore prevent the
continuation of a useless and cost-intensive developing
process. Also, exclusion of compounds proving false-nega-
tive in sub-optimal test systems could be prevented by using
suitable test systems for the detection of potential cardio-
toxicity. It is important to note that many drugs that were
withdrawn from the market due to cardiac side effects,
including Cisapride, Droperidol or Vioxx, have had other
thancardiovascularapplications.Aprominentexampleisthe
anti-inﬂammatory drug Vioxx (Merck), prescribed to more
than 80 Million people (Topol 2004), that was withdrawn
from the market in September 2004, because of increased
risks of cardiac effects at high dosage and long-term use.
Among pro-arrhythmic cardiac side effects, drug-
induced delayed repolarization of the ventricular action
potential is very common. This delay becomes visible as a
prolonged QT interval and has been associated with ven-
tricular tachyarrhythmia such as life-threatening torsade de
pointes (TdP). Most drugs that cause QT interval prolon-
gation and TdP have been shown to block the a-subunit of
the IKr channel encoded by the human ether-a-go-go-
related gene (hERG). The IKr channel produces the rapid
component of the delayed rectiﬁer potassium current IKr
which is involved in repolarization. Although the question
whether QT prolongation is a surrogate biomarker for TdP
is still under debate (Lee et al. 2010), safety assessment of
drug candidates now has to include the demonstration that
the drug does not prolong the human QT interval at ther-
apeutic and supra-therapeutic doses (ICH E14, Clinical
Evaluation of QT/QTc Interval Prolongation and Proar-
rhythmic Potential for Non-Antiarrhythmic Drugs).
Therefore, cardiac safety pharmacology aims at the
development of strategies to detect drug-induced unantic-
ipated prolongation of the QT interval during early phases
of drug development, but also other parameters were sug-
gested to serve as potential hallmarks of TdP such as tri-
angulation of the ECG shape, beat-to-beat variations or
reverse use dependence.
To test for QT prolongation already in pre-clinical set-
tings, several cell and tissue models are currently used
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in vitro systems are based on heterologous expression of
the hERG channel in non-human (CHO) or human (HEK-
239) cell lines. In these cell lines, potential interactions of
drugs with the hERG channel can be detected by several
methods. Although these cell-based systems are sensitive
and can be used for high-throughput screening, they do not
provide the human cardiac-speciﬁc environment and may
result in false-positive results. Other commonly used
models for cardiac safety pharmaco-toxicology include
isolated cardiac tissues (such as papillary muscle or Pur-
kinje ﬁbres from guinea pigs or dogs) and primary
cardiomyocytes, e.g. from rats or dogs. However, these
systems are labour-intensive, sometimes highly variable
and may raise ethical concerns due to the large animal
numbers required. In vivo models applied in cardiac
pharmaco-toxicology include hearts explanted from small
animals, such as rats or guinea pigs (Langendorff perfused
isolated heart, reviewed in Skrzypiec-Spring et al. 2007).
Whereas these heart models resemble the complex in vivo
situation better than other systems and offer the advantage
of detecting cardiotoxic effects on the whole tissue levels,
problems are related to the animal origin, inter-experi-
mental variations and high costs. Altogether, none of these
models alone is predictive enough to exclude cardiac side
effects and, according to ICH guidance document ICH
S7B, the conduction of ECG assays in conscious animals,
usually dogs, are a minimal requirement for testing of new
chemical entity (NCE) drug candidates.
A self-replicating cell source, such as pluripotent stem
cells, with the potential to differentiate into cardiomyocytes
would represent an alternative in vitro system for cardio-
toxicity. Earlier studies on murine ESC-derived cardio-
myocytes have already demonstrated the potential of ESCs
for safety pharmacology and toxicology (reviewed in
Boheler et al. 2002; Wobus and Boheler 2005). Murine
ESCs differentiating into the cardiac lineage yield several
specialized cell types of the heart, such as atrial-, ventric-
ular-, sinus nodal- and Purkinje-like cells. Cardiac-speciﬁc
genes as well as proteins, receptors and ion channels are
expressed in a developmentally controlled manner, which
closely recapitulates the developmental pattern of early
cardiogenesis in vivo (for reviews see Boheler et al. 2002;
Filipczyk et al. 2007). Genetic manipulation, addition of
extrinsic factors and extracellular matrix proteins, engi-
neering the microenvironment as well as improvements in
cultivation protocols have been shown to trigger the cardiac
differentiation process and to increase the efﬁciency of
cardiacdifferentiation(forreviewssee Filipczyk etal.2007;
Chen et al. 2008; Perino et al. 2008; Puceat 2008; Reinecke
et al. 2008; Horton et al. 2009). However, only human cell-
based in vitro systems would overcome the problem of
inter-species differences that limit the use of mESCs for
cardiotoxicity testing. So far, much progress has been made
in the differentiation of hESCs towards cardiomyocytes,
and this knowledge is now being applied to hiPSCs. In the
following sections, recent strategies for the generation of
cardiomyocytes from human pluripotent stem cells, their
characterization and methods for their enrichment will be
summarized, and the potential of these cardiomyocytes in
safety pharmacology and toxicology will be discussed.
Production of hESC-derived cardiomyocytes
for cardiotoxicity studies
Methods for cardiac differentiation of hESCs
and characterization of cardiomyocytes
Since the ﬁrst successful derivation of hESC-derived
cardiomyocytes (Kehat et al. 2001), a large number of
studies has been published on the generation of cardiac
myocytes from hESCs. Three basic methods have been
exploited and reﬁned to differentiate hESCs to cardiac
cells: EB formation, co-cultivation of hESC-derived cells
with endoderm cells and differentiation in monolayer cul-
ture induced by speciﬁc signalling factors.
(i) The method most widely applied involves the for-
mation of EBs by spontaneous aggregation of undifferen-
tiated hESCs in suspension culture (Kehat et al. 2001), but
also centrifugation-forced aggregation has been used
(Burridge et al. 2007). After several days in suspension, the
EBs are replated on speciﬁc matrices resulting in the for-
mation of spontaneously beating clusters in the EB out-
growths, which were reported to be stable for up to
3 months (He et al. 2003). However, the number of beating
EBs is highly variable and ranges from about 8 (Kehat
et al. 2001) to 70% (Xu et al. 2002), but also lower efﬁ-
ciencies of cardiac cluster formation were reported (Den-
ning et al. 2006). Similarly to mESCs, the number of
contracting EBs from hESCs was shown to depend on
several factors, including the cell line used (Mikkola et al.
2006), application of growth factors (Burridge et al. 2007;
Pal and Khanna 2007) or size of EBs (Niebruegge et al.
2009; Mohr et al. 2010). The percentage of cardiac cells
within the EBs (after dissociation) also exhibited sub-
stantial variation ranging from 2 to 70%. As previously
observed in mESCs (Maltsev et al. 1993), contracting EBs
also differed with respect to the cardiomyocyte composi-
tion: while different EBs showed various types of action
potentials (APs), each EB was populated by a predominant
type of cardiac myocytes giving rise to nodal-, atrial- or
ventricular-like types of APs (He et al. 2003). It was sug-
gested that the ability of hESC lines to produce chamber-
speciﬁc derivatives to a different degree is due to subtle
differences in the proteomes of undifferentiated hESCs
(Moore et al. 2008a).
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with END-2 cells, visceral endoderm cells derived as
permanent line from mEC cells, which provide inductive
signals necessary for cardiac differentiation (Mummery
et al. 2003). Omission of FCS and addition of ascorbic acid
markedly improved the efﬁciency of cardiac differentiation
and the number of cardiomyocytes (Passier et al. 2005).
However, there are obvious differences in the amenability
of hESCs to the differentiation induction. Even cell lines
derived in the same laboratory under identical conditions
showed marked differences in their potential to form
beating areas using the END-2 co-culture system (0–9.4%
of all aggregates; Pekkanen-Mattila et al. 2009). The END-
2 effects were shown to be, at least partially, due to a rapid
clearance of insulin from the culture medium and secretion
of prostaglandin I2 (PGI2) by END-2 cells. Consequently,
END-2-conditioned medium and a deﬁned, insulin-free
differentiation medium containing PGI2 also stimulated
cardiac differentiation of hESCs. The efﬁciency of cardiac
differentiation was further increased by addition of the p38
MAPK inhibitor SB203580 at low concentration. The
number of beating EBs was as high as nearly 80% and the
amount of cardiomyocytes was increased to up to 22% of
the whole cell population (Graichen et al. 2008; Xu et al.
2008a).
(iii) More recently, methods for directed cardiac differ-
entiation starting from FL-free monolayer hESC-derived
colonies in deﬁned media were developed. These methods
are based on novel insights into molecular events during
early human cardiogenesis partially derived from studies on
gene expression patterns in differentiating hESCs (Beqqali
et al. 2006). The differentiation protocols involve the addi-
tion of growth factors at speciﬁc time points of in vitro
differentiation to mimic embryogenesis in vivo. In a ﬁrst
study, the differentiation was initiated by activin A, an
inducerofmesendoderm,andBMP-4specifyingmyocardial
lineage commitment in hESCs. Resulting cell populations
showed markers of early cardiac cells (Yao et al. 2006).
Further development of this approach yielded consis-
tently[30% cardiomyocytes that couldbe enriched to more
than80%byPercollgradientcentrifugation(Laﬂammeetal.
2007).
Based on studies of human and mouse heart develop-
ment and mESCs, efforts were undertaken to derive cardiac
progenitor cells from hESCs. Such cardiac-restricted, non-
tumourigenic, expandable progenitor cell populations
could serve as starting material for the production of
deﬁned cardiac cell types of high purity (reviewed in Pe-
rino et al. 2008). Keller and co-workers identiﬁed a pop-
ulation of KDR
low/C-Kit
neg cells with the potential to
develop into cardiac, smooth muscle and endothelial cells.
Using a protocol based on the formation of a primitive-
streak-like population followed by the induction of cardiac
mesoderm, this approach resulted in a high fraction (up to
50%) of functional cardiomyocytes (Yang et al. 2008). Via
lineage tracing in hESCs, Chien and co-workers identiﬁed
a population of ISL1 ? cells that could be expanded in
vitro, puriﬁed to relative homogeneity and were able to
develop at high efﬁciency into cells expressing genes of the
major cardiac cell types (Bu et al. 2009).
Human ESC-derived cardiomyocytes have been ana-
lysed extensively with respect to molecular, cellular and
functional characteristics including gene expression pro-
ﬁles, protein abundance, ultrastructure, electrophysiologi-
cal features and pharmacological properties. During
differentiation in vitro, hESC-derived cardiomyocytes
progress towards an adult phenotype resulting in changes
of structural and electrophysiological properties (Snir et al.
2003; Sartiani et al. 2007; Satin et al. 2008). Gene
expression proﬁles of developing hESC-derived cardio-
myocytes were found to be reminiscent of contractile cells
in the developing heart, although many genes expressed in
the adult heart are also expressed in differentiating
cardiomyocytes (Beqqali et al. 2006; Synnergren et al.
2008). In a recent study a unique molecular signature
characterized by a transcription factor network linked to
the PPAR signalling pathway was identiﬁed (Xu et al.
2009), but so far, transcriptome proﬁling was only per-
formed in cells differentiated up to 25 days.
Human ESCs differentiate into pacemaker-, atrial- and
ventricular-like cells representing cardiomyocytes expres-
sing multiple types of ventricular, atrial and nodal-like APs
of the heart (He et al. 2003; Mummery et al. 2003).
Cardiomyocytes derived from hESCs show spontaneous
contractions indicating the presence of a functional exci-
tation–contraction coupling system that is modulated via
a- and b1/b2-adrenoceptors and muscarinic responses
(Reppel et al. 2004; Norstrom et al. 2006; Brito-Martins
et al. 2008). In addition, these cells exert functional Na
?-,
K
?- and Ca
2?-dependent ion channel activities.
However, there are some differences with respect to
structural and electrophysiological properties of human
ESC-derived cardiac cells in comparison with mature heart
or mESC-derived cardiomyocytes: (1) Although develop-
ing hESC-derived cardiac cells show gross morphological
changes coupled with a progressive increase in the amount
and organization of contractile material (culminating in the
presence of well-deﬁned sarcomeres) and withdrawal from
cell cycle, even after extended culture time they lack a
developed T tubule system typical for cardiomyocytes of
the adult heart. (2) In contrast to mESC-derived cardio-
myocytes, limited binucleation was observed in cardio-
myocytes differentiated from hESCs (Snir et al. 2003).
(3) hESC-derived cardiomyocytes contained smooth
muscle proteins typically for foetal, but not adult, human
cardiac cells. (4) Electrophysiological properties showed
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from hESC-derived cardiomyocytes leading to a slightly
depolarized membrane potential. As observed in foetal
cardiomyocytes, hESC-derived cardiomyocytes exhibited
the If channel and showed a low Vmax. Moreover, imma-
turity of intracellular Ca
2? handling of hESC-derived
cardiomyocytes was reported, although to a different extent
(Dolnikov et al. 2006; Liu et al. 2007; Satin et al. 2008;
Zhu et al. 2009; Sedan et al. 2010).
Strategies for enrichment of hESC-derived cardiomyocytes
Efﬁcient cardiac differentiation of hESCs is dependent on
speciﬁc factors that critically affect cardiac differentiation,
speciﬁcally, by concentration- and time-dependent activa-
tion of cardiac signalling pathways (reviewed in Filipczyk
et al. 2007; Perino et al. 2008; Sarkar and Rao 2009).
However, no single protocol has led to pure populations of
functional human cardiomyocytes so far. Cell populations
resulting from various differentiation strategies usually
contain a mixture of different cell types. Therefore, several
methods and procedures for the generation of pure car-
diomyocyte populations by application of enrichment and/
or selection procedures have been established.
At ﬁrst, manual dissection of contracting cardiac cells
(Kehat et al. 2001) and separation by Percoll density-gra-
dient centrifugation (Xu et al. 2002; Xu et al. 2006) were
used, which allowed a considerable enrichment of cardio-
myocytes. However, these methods are either labour-
intensive or disadvantageous with respect to insufﬁcient
purity and lack of scalability. More recent studies tried to
identify surface markers endogenously expressed by
cardiomyocytes, which could be used for cell sorting (Rust
et al. 2009; Van Hoof et al. 2010). However, these methods
did not yield cardiac cell populations of high purity, most
likely due to low abundance of cardiac-speciﬁc proteins on
the cell surface or to poor antigen–antibody avidity.
Another recent method for enrichment of cardiomyocytes
derived from hESCs or hiPSCs is based on the high
abundance of mitochondria in developing cardiomyocytes
(Hattori et al. 2010). Staining of differentiating EBs with a
mitochondrial dye and subsequent FACS sorting resulted in
cardiomyocyte populations of more than 99% purity. After
washout of the dye, cells showed typical characteristics of
ESC-derived cardiomyocytes and were able to integrate
and survive in the murine heart.
Other methods for cardiomyocyte enrichment depend on
genetic modiﬁcation of hESCs and include positive selec-
tion for the expression of reporter and/or marker genes
driven by cardiac-speciﬁc promoters in hESCs (lineage
selection) or negative selection against proliferating cells in
the heart cell population using a suicide gene approach.
These strategies allowed an efﬁcient enrichment of
cardiomyocytes. For example, positive selection for cells
expressing a puromycin-resistance gene driven by the
cardiac-speciﬁc MYH6 promoter resulted in more than
90% a-actinin-positive cells, while negative selection
against Herpes simplex virus thymidine kinase (HSV-TK)
expression in proliferating (non-cardiac) cells yielded cell
populations comprised of 33% cardiomyocytes (Anderson
et al. 2007). In another study, negative selection against
HSV-TK expression was combined with positive selection
for cells expressing the neomycine-resistance gene driven
by the mouse a-myosin heavy chain (MHC) promoter,
which allowed for an enrichment of cardiomyocytes to
nearly 100% purity. Notably, no tumour formation was
detected after transplantation of enriched cells into SCID
mice (Xu et al. 2008b). In another study, differentiation of
hESCs expressing the eGFP reporter gene driven by the
cardiac-speciﬁc human myosin light chain-2 V (MLC-2 V)
promoter and subsequent FACS sorting of differentiated
cells resulted in populations containing more than 90%
cells that expressed cardiac-speciﬁc genes (Huber et al.
2007). Thus, lineage selection methods for cardiomyocyte
enrichment seem to be efﬁcient. Moreover, while the (viral
or non-viral) genetic modiﬁcation of cells might be a risk
for in vivo applications because of possible tumour for-
mation due to uncontrolled insertion of extrinsic genes,
they should be of only minor importance for in vitro
applications.
In summary, although in vitro derived, hESC-derived
cardiomyocytes exhibit several characteristics of mature
human cardiomyocytes, they resemble cardiomyocytes of a
foetal stage. However, with respect to their electrophysio-
logical properties, they show characteristics that make
them a promising tool for safety pharmacology and drug
development. Importantly, recent studies indicate that
cardiomyocytes derived from hiPSCs have characteristics
identical or very similar to those of hESC-derived cardiac
cells (see ‘‘Human iPS cell-derived cardiomyocytes for
in vitro pharmaco-toxicology’’).
Application of hESC-derived cardiomyocytes
in pharmaco-toxicology
In general, hPSC-derived cardiomyocytes could have sig-
niﬁcant advantages over in vitro and in vivo systems cur-
rently used in cardiac safety pharmacology. (1) Most
importantly, hPSC-derived cardiomyocytes represent
human cardiomyocytes that express the characteristic car-
diac-speciﬁc genes, giving rise to human-speciﬁc proteins
and signalling components. Cardiomyocytes display APs
with cardiac-like morphologies and express genes for
characteristic ion channels, such as the If pacemaker, Na
?
and L-type Ca
2? and several potassium channels. (2)
hPSC-derived cardiomyocytes are genetically identical and
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expected that, in the near future, cardiomyocytes can be
produced at large numbers and at reasonable high purity.
(3) By use of hPSC-derived cardiomyocytes drug effects on
electrophysiological properties can be analysed at the sin-
gle cell level and in a network of inter-connected cells of
cardiac clusters. (4) hPSCs are accessible to genetic mod-
iﬁcation, which are also present in the respective hPSC-
derived cardiomyocytes. In addition, cardiomyocytes can
be generated from hESCs derived from PGD embryos
diagnosed for cardiac-speciﬁc mutations or from iPS cells
derived from donors with an inherited cardiac disease or
with a cardiac-speciﬁc phenotype representing a potential
drug risk. (5) Since hPSC-derived cardiomyocytes are of
human origin, the predictive value of toxic effects will not
be restricted by species-speciﬁc differences inherent to
animal-based test systems.
Most studies on cardiac differentiation of hPCSs were
performed with hESCs, and the characterization of hESC-
derived cardiomyocytes usually involved the pharmaco-
logical characterization as well as the investigation of
cardio-active agents, such as ion channel blockers and
substances with known pro-arrhythmogenic effects on
cardiomyocytes (reviewed in Denning and Anderson
2008). However, information on the applicability of hESCs
to safety pharmacology is still restricted. To assess the
respective potential and the limitations of hESC-derived
cardiomyocytes, sophisticated dose–response studies must
be performed, including the investigation of drug responses
on hESC-derived cardiomyocytes at concentrations mea-
sured in the plasma of patients under treatment. Moreover,
side-to-side comparisons of drug responses of hESC-
derived cardiomyocytes and currently used in vitro and in
vivo models are required. Finally, a broad application of
hPSC-based in vitro systems will require its use in HTP
screening settings. In the recent past, several studies were
published that aimed towards these goals. The main focus
of this research was to present proof-of-concept that hESC-
derived cardiomyocytes are able to mirror cardiac func-
tions with respect to drug side effects and that these effects
were at least comparable to those detected in currently used
cell and tissue models.
The potential usefulness of hESC-derived cardiac cells
forsafety pharmacologywasshowninseveralrecentstudies
(Caspi et al. 2009; Braam et al. 2010; Jonsson et al. 2010;
Liang et al. 2010; Otsuji et al. 2010; Pekkanen-Mattila et al.
2010; Peng et al. 2010). In general, hESC-derived cardio-
myocytes were reactive to several drugs in a manner that
resembles mature cardiomyocytes (Caspi et al. 2009). For
example,E-4031(aselectiveIKrblocker)andSotalol(aclass
III anti-arrhythmic agent blocking IKs) prolonged action
potential duration by mainly effecting terminal repolariza-
tion.ContinuousblockadeofIKrresultedinthedevelopment
of after-depolarizations and treatment with class I and III
anti-arrhythmic substances and cisapride led to a dose-
dependent increase in the ﬁeld potential duration. Adminis-
tration of class I anti-arrhythmic agents (quinidine and pro-
pafenone) resulted in dose-dependent conduction slowing
and reduced beating rate, while the gap junction uncoupler
1-heptanol caused slowing of conduction with higher con-
centrations leading to development of conduction blocks
(Caspi et al. 2009). In another study (Braam et al. 2010), QT
intervalprolongationcausedbyseveralagentsanddrugswas
measuredbymulti-electrodearray(MEA)chipsseededwith
microdissected cardiac clusters consisting of mainly ventri-
cle-like cells. MEA recordings showed dose-dependent QT
interval prolongation after treatment with repolarization-
prolonging anti-arrhythmic drugs. While anti-arrhythmic
drugs caused QT interval prolongations at concentrations
observedinthehumanplasmaofpatientsundertherapywith
these drugs, several non-cardiac drugs associated with QT
intervalprolongation andTdP showeda signiﬁcanteffect on
the AP duration only at concentrations above typical plasma
levels, which underlines the necessity to deﬁne adequate
safetymargins.However,thehESC-basedsystemshowedan
advantage over the classical hERG assays that would have
led to a misclassiﬁcation of some of the substances investi-
gated. Moreover, the use of a six-well MEA system in this
study could be a ﬁrst step towards the establishment of test
systems which allow for a higher throughput of test sub-
stances. In a further study, drug effects on parameters addi-
tionaltoAPprolongationweredetermined,thetriangulation
of the AP shape and short-term variability of polarization
(STV; Jonsson et al. 2010). Both parameters are important
for the assessment of a pro-arrhythmic potential, since
changes are associated with the appearance of early after-
depolarizations (EAD) as a trigger of TdP. The use of addi-
tional parameters in the risk assessment of TdP has been
suggested since prolongation of AP alone is not considered
to be an adequate predictor of pro-arrhythmic events
(Hondeghem2008).InthestudybyJonssonandco-workers,
E-4031 caused AP prolongation in ventricular-like hESC-
derived cardiac clusters and importantly, occurrence of
EADs was preceded by an increase in both triangulation and
STV. Interestingly, there was a clear positive correlation
between the ventricular phenotype of the cardiac clusters
(beating frequency\50 bpm; action potential duration at
90% depolarization (APD90)[300 ms) and the occurrence
of EADs, which are the cellular events underlying the onset
of TdP in the heart.
In addition, several recent studies aimed at the com-
parison of safety pharmacology assays currently used,
namely those using canine or rabbit Purkinje ﬁbres (PFs),
with hESC-derived cardiomyocyte-based assays. For
example, Jonsson and co-workers found a more pro-
nounced ADP prolongation by E-4031 treatment of rabbit
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tion and SVT values were comparable after treatment with
this drug in both systems (Jonsson et al. 2010). For all
parameters, baseline values were higher in the hESC-
derived cardiac cells compared to rabbit PFs. This could be
due to a lower and more heterogeneous coupling in hESC-
derived cardiac clusters than in the PFs. In another study,
the pharmacological proﬁle of hESC-derived cardiomyo-
cytes was compared to the proﬁle of rabbit and canine PFs
(Peng et al. 2010). According to this study, hESC-derived
cardiomyocytes were highly sensitive to pharmacological
blockage of a multitude of ion channels resulting in
respective AP alterations. For most agents tested, the sen-
sitivity of hESC-derived cardiac cells was higher than
those of canine or rabbit PFs and species-speciﬁc differ-
ences were demonstrated (for example, IKs blockage by
chromanol 293b that is absent in rabbit PFs; IKr blockage
by terfenadine that is absent in canine PFs and less sensi-
tive in rabbit PFs). Whether the higher sensitivity of hESC-
derived cardiac cells observed in this study is due to spe-
cies differences in ion channel expression, experimental
settings, lack of diffusion barriers or uptake of substances
by cytoplasmic structures (present in PFs, but absent in
hESC-derived cells) remains to be determined. Clear
advantages of the hESC-based assay compared to PFs were
a higher stability and shorter duration, the latter probably
due to more immediate drug effects in the hESC-derived
cardiomyocytes.
In another recent study, the induction of early depolar-
izations by sotalol and quinidine was compared between
mouse and human ESC-derived cardiomyocytes (Liang
et al. 2010). While repolarization-prolonging anti-arrhyth-
mica at relatively high concentrations provoked EADs in
all mouse ESC-derived clusters tested, EADs were only
occasionally observed in hESC-derived cardiomyocytes
indicating either differences in the sensitivity of the spe-
ciﬁc ion channels or in different contribution of ion chan-
nels to the repolarization phase. Nevertheless, all drugs
tested in this study showed similar effects on hESC-derived
cardiac clusters as detected in earlier studies using animals
or other in vitro test systems (Liang et al. 2010).
As discussed earlier, hPSC-derived cardiomyocytes pass
through a process of maturation during in vitro cultivation.
Accordingly, maturity increases with culture time and
pharmacological analyses are usually performed on
immature ESC-derived cardiac cells. However, despite
their immature phenotype, ESC-derived cardiomyocytes
showed close similarities to mature cardiomyocytes with
respect to expression proﬁle and functional characteristics,
which qualiﬁes hESC-derived cardiac cells for safety
pharmaco-toxicology. It is still a matter of debate, whether
appropriate drug testing will require more mature cardio-
myocytes. Recently, Otsuji and colleagues demonstrated
that hESC-derived cardiomyocytes selected for pacemaker
function could be cultured for up to 1 year by continuous
replating, which resulted in a more mature phenotype at the
gene expression and functional levels (Otsuji et al. 2010).
However, QT interval prolongation by E-4031 only
occurred when hESC-derived cardiac cells were cultured as
3D aggregates, while cultivation under adhesive conditions
led to cardiomyocytes with shortened QT intervals. The
reason for this observation is not clear, but could be due to
speciﬁc characteristics of the cell line used in this study
(KhES-1). This cell line is characterized by an unusual low
spontaneous formation of contractile EBs (less than 1%)
and cardiac differentiation was only achieved by co-culture
with END-2 cells.
Differences in the ability of hESC lines to develop into
the cardiac lineage were already observed in previous
studies. It should be noted that the number of hESC lines
used for cardiac differentiation so far is very limited. The
analysis of more than 70 original studies published on
cardiac differentiation of hESCs between 2001 and 2009
revealed that only few cell lines (three of WiCell, two of
ES Cell International and one of Harvard University) or
their derivatives were used in more than three cardiac
differentiation studies. Twenty-nine cell lines were used
only in a single study, and their cardiac differentiation
potential needs to be conﬁrmed (Lo ¨ser & Wobus,
unpublished).
Until now, the evaluation of hPSC-derived cardiomyo-
cytes in safety pharmacology focused mainly on the
detection of unforeseen side effects on the electrophysiol-
ogy of human heart cells. However, a major problem linked
to the use of some cytostatic drugs is cardiac toxicity,
which is an important complication of high-dose chemo-
therapy (reviewed in Albini et al. 2010). While some anti-
cancer drugs exert their effects on the cardiovascular sys-
tem rather in the periphery, for example, by increasing
peripheral vascular resistance and blood pressure or by
affecting the coagulation system, others directly damage
cardiac myocytes. Mechanisms involved in anti-cancer
therapy-induced heart damage include, for example, alter-
ations of cellular signalling in cardiomyocytes (perturbing
mitochondrial functions and activating apoptosis path-
ways), the stimulation of free radical production or massive
histamine release resulting in conduction disturbances and
arrhythmias. A prominent example of unexpected cardiac
side effects of anti-cancer drugs is trastuzumab (Hercep-
tin), a monoclonal antibody binding to the membrane
protein HER-2 that is over-expressed in some cancers.
Trastuzumab is approved for breast cancer therapy, but
application resulted in heart failure in up to 4% and
decreased cardiac function in up to 10% of patients,
especially when co-administered with anthracyclines
(Chien 2006). The cellular target of the cardiac side effects
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drug was not detected prior to its use in phase III clinical
trials. In general, a reliable prediction of cardiotoxicity is
hampered due to the still fragmentary understanding of the
molecular basis underlying cardiotoxicity, the lack of rec-
ognized surrogate endpoints and the availability of ade-
quate pre-clinical test systems.
In this respect, it is of interest to note that recent studies
started to establish endpoints for cardiotoxicity that could
be useful in toxicological test systems based on hESC-
derived cardiac sells. For example, release of cardiac tro-
ponins into the mediums is a measure for drug-induced
decrease in cardiac cell viability. Therefore, it was sug-
gested to use human troponins I and II as well as cardiac
natriuretic peptides as biomarkers to predict potential car-
diac damage by chemotherapy (Dolci et al. 2008).
Recently, the establishment of a hESC-derived cardiomy-
ocyte-based assay was reported, in which the doxorubicin-
induced release of troponin T and fatty acid binding protein
3 (FABP3) from cardiac cells was determined by surface
plasmon resonance (SPR) biosensing (Andersson et al.
2010). The combination of additional markers with
improved human cell-based in vitro systems will be helpful
for cardiac toxicity screening of drugs such as anti-cancer
agents. In addition, such improved in vitro systems could
also facilitate the analysis of the mechanisms underlying
cardiac side effects of anti-cancer drugs.
To obtain heart cells of a more mature phenotype, the
generation of three-dimensional (3D) so-called engineered
heart tissue (EHT) couldbe an option. Mechanical stretch as
maturation-inducing factor has been included into this
model. Several methods for the development of EHT using
animal (mainly neonatal rat) cardiomyocytes were devel-
oped (Li et al. 2000; Shimizu et al. 2002; Zimmermann
et al. 2002). The generation of 3D EHTs from hESC-
derived cardiac tissue was also performed by seeding
hESC-derived cardiomyocytes either alone or in combina-
tion with endothelial progenitor cells and embryonic
ﬁbroblasts on degradable scaffolds (Caspi et al. 2007;
Lesman et al. 2010). However, these studies were per-
formed with the major goal of analysing the engraftment,
viability and functionality of human EHTs after transplan-
tation into immune-suppressed animals, and not in respect
of the establishment of models for drug screening or safety
pharmacology. Interestingly, in a recent study, ﬁbrin-based
mini-EHTs containing neonatal rat heart cells were applied
to detect changes in relaxation time and contractile forces
following drug treatment (Hansen et al. 2010). Of note,
contractile activity in these experiments was measured in a
24-well scale using an automated detection system. Further
studies have to show whether similar approaches can be
developed for hESC-derived cardiac cells.
Human iPS cell-derived cardiomyocytes
for in vitro pharmaco-toxicology
With the successful cardiac differentiation of hiPSCs, the
use of hiPSC-derived cardiomyocytes for pharmaco-toxi-
cological studies comes into view. Cardiomyocytes were
differentiated from hiPSCs by both the classical EB
method and by co-culture with END2 cells (Yokoo et al.
2009; Zhang et al. 2009; Zwi et al. 2009; Freund et al.
2010). In addition, ISL1
? progenitor cells isolated from
hiPSCs were induced to differentiate into the major cardiac
cell types (Moretti et al. 2010a).
Cardiomyocytes differentiated from hiPSCs were found
to be very similar to those derived from hESCs with respect
to morphology, gene expression patterns and electrophys-
iological features. The cardiomyocytes showed APs of
nodal-, ventricular- and atrial-like phenotypes, respon-
siveness to pharmacological stimulation and sensitivity to
ion channel blockers. In one study, hiPSC-derived cardiac
cells even exhibited a higher maturation grade with respect
to calcium signalling than cardiomyocytes derived from
hESCs (Gai et al. 2009). Moreover, cardioactive drugs had
the same effect on contractility and beating frequency in
hiPSC- and hESC-derived cardiomyocytes, and several
drugs caused the expected changes of QT-interval duration
(Yokoo et al. 2009; Zwi et al. 2009).
Although the number of hiPSC lines investigated with
respect to cardiac differentiation is still rather low and the
impact of factors such as residual expression of repro-
gramming genes on cardiac differentiation remains to be
determined, it is obvious that hiPSC-derived cardiomyo-
cytes will be a valuable source for cardiac cells in drug
discovery and safety pharmacology. This has also attracted
the interest of the pharmaceutical industry. For example,
the Madison-based company Cellular Dynamics Interna-
tional (CDI) has launched hiPSC-derived iCell
TM Cardio-
myocytes designed to aid drug discovery and improve the
predictability of compound efﬁcacy and toxicity (Cellular
Dynamics, Press release of Dec 12th, 2009). Moreover,
there is some hope that in the future patient-speciﬁc hiPSCs
could be commonly used in safety pharmacology for
selecting optimal medication for speciﬁc patients or patient
groups. For example, there may be different causes for a
higher susceptibility of certain patients to drug-induced QT
interval prolongation and TdP, e.g. speciﬁc mutations in
genes coding for ion channels, and genetic testing for
respective subtypes would be difﬁcult and erroneous
(Tester et al. 2006). In these cases, the use of patient-
speciﬁc hiPSC-derived cardiomyocytes could be an
attractive way to detect patient-speciﬁc risks, such as
prolonged QT intervals following treatment with certain
drugs.
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screening, cardiac cells derived from patients may also be
useful to investigate the pathophysiology of cardiac dis-
orders. For example, hiPSCs generated from patients with
LEOPARD syndrome were successfully differentiated into
cardiomyocytes (Carvajal-Vergara et al. 2010). Although
there were some drawbacks with respect to the variability
of the cell populations, cardiac cells showed some char-
acteristics consistent with cardiac hypertrophy commonly
found in patients with this syndrome. In addition, phos-
phorylation of certain proteins possibly involved in the
diseased phenotype was altered. Recently, cardiac cells
were also derived from two patients with an inherited form
of the LQT syndrome (Moretti et al. 2010b). These cells
showed disease-speciﬁc anomalies in the duration of action
potentials, the action potential rate adaptation and IKs
currents. It was shown that in the speciﬁc mutant channel
trafﬁcking to the plasma membrane was suppressed in a
dominant-negative manner. These ﬁrst studies clearly
underline the potential value of patient-speciﬁc hiPSC-
derived cardiomyocytes for a deeper understanding of
disease mechanisms and for the identiﬁcation of novel drug
targets.
Future challenges of cardiotoxicity testing using human
pluripotent stem cells
It was shown over the past years that functional cardio-
myocytes can be obtained from both hESCs and hiPSCs.
These cells are of human origin, express the genes for
important ion channels, are responsive to external stimuli
and show the anticipated response to a broad range of
pharmaceutically active agents. Therefore, cardiomyocytes
derived from hPSCs may offer the basis for the develop-
ment of novel, human-speciﬁc platforms for assessing the
safety of novel compounds. However, to make hPSC-
derived cardiomyocytes widely applicable to screening
procedures and to gain the acceptance of regulatory
authorities, several problems have to be solved:
(i) Efﬁcient differentiation of hPCSs and enrichment of
cardiomyocytes Although there is much progress in car-
diac differentiation of hPSCs, the understanding of the
differentiation process and the characteristics of deﬁned
human cardiac progenitor cells is still limited and further
research in this ﬁeld is required. A deeper understanding of
factors and signalling pathways involved in cardiac dif-
ferentiation is the basis for the development of improved
differentiation protocols. In the longer term, reliable, efﬁ-
cient and standardized differentiation protocols have to be
established that can be reproduced with different pluripo-
tent cell lines in various laboratories. Since hPSC differ-
entiation usually results in a mixture of more and less
mature cardiomyocytes of different cardiac phenotypes
(Pekkanen-Mattila et al. 2010), strategies for enrichment of
cells of a speciﬁc phenotype and a certain degree of
maturity will be needed.
(ii) Maturation of stem cell-derived cardiomyocytes So
far, hPSC-derived cardiomyocytes resemble in some
aspects a foetal, relatively immature cardiac phenotype.
Although currently available cells show a panel of elec-
trophysiological and pharmacological similarities to the
human heart, the generation of cells with a phenotype
more similar to human adult cardiomyocytes will be
necessary to recapitulate the situation in the human heart.
One possible approach to obtain more mature cardio-
myocytes could be culturing the cells for extended periods
of time which is, however, labour-intensive (Otsuji et al.
2010). In addition, mechanical loading was shown to
stimulate maturation of cardiomyocytes derived from
mouse ESCs cultured on elastic polymer scaffolds (Gwak
et al. 2008). Furthermore, it was shown recently that non-
cardiomyocytes within the differentiating cell population
drive ion channel development and electrophysiological
maturation of hESC-derived cardiomyocytes (Kim et al.
2010a). It will be interesting to ﬁgure out the nature of
these cells and the instructive signals that promote car-
diomyocyte maturation.
(iii) Scaling up hESC differentiation Current methods for
differentiation of hESCs to cardiomyocytes suffer from a
poor scalability. For example, EB generation and protocols
for extended culture are labour-intensive and difﬁcult to
scale up. In addition, differentiation is still costly due to the
requirement of expensive growth factors. Thus, protocols
for production of hPSC-derived cardiomyocytes are
required in which manual labour is minimized and costs are
signiﬁcantly reduced, e.g. by using more cost-effective
deﬁned chemical compounds. Efforts to scale up cardiac
differentiation in either stirred bioreactors (Niebruegge
et al. 2009) or suspended microcarrier (Lecina et al. 2010)
cultures have been initiated but need further development
and standardization.
(iv) Comparison with currently used standards In recent
studies, proof-of-principle was provided that hPSC-derived
cardiomyocytes are sensitive to a panel of agents with well-
known effects on the human heart, and, in some studies,
cardiac electrophysiology was compared to that observed
in existing animal-derived test systems. However, thorough
side-by-side comparisons of hESC-derived cardiomyocytes
and established in vitro and in vivo models for drug testing
have still to be done. This will be the prerequisite to assess
the potential and limitations of hESC-based systems for
detection of cardiotoxicity. Ideally, the proof of the use-
fulness of hESC-derived cardiomyocytes would be the
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stages of drug development or in clinical trials.
In summary, the use of hPSC-derived cardiomyocytes
for safety testing is a promising option, but requires more
efﬁcient and reproducible differentiation protocols that
allow for the production of mature cardiomyocytes at large
numbers. The hPSC-derived cardiomyocytes have to show
essential characteristics of human heart cells, should be
readily accessible to cryopreservation and must be suitable
for use in HTP screening platforms.
The potential of hepatocytes generated from human
pluripotent stem cells for safety pharmacology
and toxicology
The need to test drug-induced hepatotoxicity
Drug-induced liver injury (DILI) is a serious complication
of clinical routine therapy and among the most frequent
reasons for withdrawal from the market of approved drugs.
DILI is the major cause of acute liver failure and of liver
transplantations in Western countries. In a recent search of
several DILI registries, 298 approved drugs were identiﬁed
that caused liver injury as a side effect. A total of 265 of
these drugs were associated with acute liver failure and six
have been suspended or withdrawn due to hepatotoxicity
either in the US or in Europe (Suzuki et al. 2010). In
addition, also herbal products have been widely associated
with hepatotoxicity (reviewed in Seeff 2007).
The mechanisms by which drugs and their metabolites
exert liver toxicity are complex and only partially under-
stood. Mechanisms for DILI include cell stress imposed by
reactive metabolites (e.g. depletion of glutathione or bind-
ing to enzymes and lipids), direct targeting of mitochondrial
functions (e.g. ATP depletion or inhibition of b-oxidation
causing steatosis) and immune reactions triggered by drugs
or their metabolites. These processes ultimately result in
apoptotic or necrotic cell death (reviewed in Russmann
et al. 2009). While some drugs cause a reproducible and
dose-dependent liver damage in several animal species and
usually can be detected in pre-clinical development, a large
proportion of DILI in man occurs infrequently, partially
only after long-time treatment, without obvious dose
dependency and in an unpredictable fashion (‘‘idiosyn-
cratic’’ hepatotoxicity). Idiosyncratic hepatotoxicity may
depend on many individual ‘‘risk’’ factors such as genetic
predisposition, individual differences in liver metabolism or
environmental factors (reviewed in Chalasani and Bjorns-
son 2010).
Currently, there is no in vitro system that mirrors the
complex functions of the human liver. Considerable dif-
ferences among species in the activities of drug
metabolizing enzymes and the production of hepatotoxic
metabolites in a species-speciﬁc manner hamper the use of
classical pre-clinical animal models and animal cell-based
in vitro systems for the prediction of hepatic toxicity in
humans. Hepatotoxic effects may become only apparent in
human beings, and unexpected human liver toxicity is one
of the main causes for failure of promising drug candidates
in development. To assess potential DILI in drug devel-
opment, human cell systems are needed that reproduce
fundamental processes involved in hepatotoxicity and can
predict human liver toxicity with high reliability.
To date, isolated primary human hepatocytes (pHHs) are
the most suitable in vitro cell models for drug metabolism
and hepatocyte toxicity studies (reviewed in Hewitt et al.
2007). Hepatocytes are the major cell type of the liver and,
when cultured under appropriate conditions, retain many
physiological functions of liver cells, but only for limited
time. pHHs can be used to investigate many aspects of
DILI, such as cell viability, formation of toxic drug
metabolites, impairment of mitochondrial function or
inhibition of the biliary transport system. The major
problems that limit the use of pHHs in standard hepatocyte
toxicity testing are the limited availability and the restric-
ted in vitro proliferation capacity. In general, the use of
pHHs is highly expensive, and supply with freshly isolated
hepatocytes is unpredictable. In addition, cultured primary
hepatocytes lose their differentiated phenotype (=dedif-
ferentiation) even under optimized culture conditions, and
metabolic functions critical for investigation of drug
metabolism and toxicity decline over time. Moreover, there
are considerable variations between hepatocyte prepara-
tions due to a variety of factors such as health, diet and
medication of the donor, genetic polymorphisms between
donors and differences in the epigenetic status of relevant
genes resulting in diversity of metabolic phenotypes.
Notably, expression of genes for cytochrome P450 proteins
(CYP450s) critical for phase I metabolism strongly varies
between hepatocyte preparations from different donors
which may confound data interpretation.
As an alternative to primary hepatocytes, human hepa-
tocellular carcinoma cell lines that exhibit partial liver cell
characteristics have been frequently used for the investi-
gation of certain aspects of liver metabolism and toxicity
(reviewed in Donato et al. 2008), but their use is limited
due to low expression of crucial hepatocyte-speciﬁc genes
and no or only low enzyme activities of the CYP450 family
members that are critical for phase I metabolism.
In addition, attempts were undertaken to derive func-
tional hepatic cells from somatic stem cells from outside
the liver. First data on the contribution of un-fractionated
bone marrow-derived stem cells to liver regeneration were
published in 1999 (Petersen et al. 1999), but the concept of
trans-differentiation was challenged by others (Terada et al.
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describing hepatic differentiation of other human cells, for
example, blood monocytes (Ehnert et al. 2008) and mes-
enchymal stem cells (MSCs; reviewed in Ochiya et al.
2010). According to these reports, hepatocyte-like cells
expressed a panel of liver-speciﬁc genes and proteins.
However, although liver functions after transplantation of
such cells into rodents could be improved in certain
experimental settings, their functional characteristics were
limited in most cases. Moreover, a broader use of MSC-
derived hepatocytes in screening studies for hepatotoxicity
has not been reported so far, obviously because of
restricted in vitro proliferation and differentiation potential
and lack of standardization. It has to be shown whether and
to what extent these hepatocyte-like cells may be able to be
used as human in vitro cell system.
Consequently, there is a strong need for human-speciﬁc
in vitro test systems that mirror critical characteristics of
liver cells, and present efforts are directed towards the
establishment of PSC-derived hepatocyte-like cells. Here,
the generation and characterization of hepatocyte-like cells
from hESCs and hiPSCs will be presented.
Generation of hepatocyte-like cells from hESCs
In early studies, mouse ESCs were differentiated sponta-
neously or by addition of growth factors (Abe et al. 1996),
which resulted in the formation of hepatocytic cells
expressing hepatocyte-speciﬁc genes (reviewed in Lavon
and Benvenisty 2005). More advanced protocols for the in
vitro generation of hepatocyte-like cells from ESCs were
predominantly based on data of mouse liver development
(reviewed in Si-Tayeb et al. 2010a). In brief, during gas-
trulation deﬁnitive endoderm (DE) develops from epiblast
cells that transit the most anterior region of the primitive
streak. Formation of DE in the early embryo strongly
depends on transforming growth factor (TGF)-b and Wnt-
signalling. Further speciﬁcation to cells of the hepatic
epithelial lineages involves signalling from the developing
cardiac mesoderm and the septum transversum, which
provide FGF and BMP signalling, respectively. Cells then
start to proliferate and to invade the stroma of the septum
transversum mesenchyme thereby forming the liver bud
composed of bi-potent cells that express early hepatocytic
and biliary markers. Colonization of the liver bud by
hematopoietic cells and autocrine signalling further stim-
ulate liver development. Induction of Notch signalling
promotes differentiation along the cholangiocytic lineage,
while hepatocyte growth factor (HGF) excreted by the
septum transversum and non-parenchymal liver cells sup-
ports differentiation into foetal hepatocytes. Regional
speciﬁcation of hepatocytes is regulated by a complex
network of transcription factors including b-catenin and
hepatocyte nuclear factor (HNF)-4a, and further maturation
is stimulated, for example, by the action of oncostatin M
(OSM) mainly produced by hematopoietic cells and of
glucocorticoids.
Many efforts have been undertaken to obtain mature and
metabolically active hepatocytes from hESCs, and up to
now, there are reports from more than 20 research groups
describing the establishment and optimization of differen-
tiation protocols (reviewed in Baxter et al. 2010). Most
strategies rely on the in vitro recapitulation of develop-
mental processes and involve the application of soluble
growth factors, co-culture with hepatic and non-hepatic cell
types and reconstruction of an extracellular matrix (ECM).
In addition, a positive effect of histone deacetylase inhib-
itors such as sodium butyrate on hepatic differentiation was
observed. In some cases, these approaches were supple-
mented by introduction of reporter genes driven by liver-
speciﬁc promoters into hESCs or hepatic progenitors to
trace differentiated cells. In general, the majority of recent
protocols for hepatocyte differentiation of hESCs include
three major steps: (1) the differentiation of hESCs into DE
cells, followed by (2) the speciﬁcation into hepatic pro-
genitor cells and (3) maturation into hepatocyte-like cells
(see Baxter et al. 2010).
Methods for hepatic differentiation of hESCs were
established to mimic processes of lineage commitment
during embryogenesis by use of multi-stage protocols
starting from either hESC-derived EBs or monolayer cul-
tures. EB formation in the presence of serum and addition
of growth factors (Rambhatla et al. 2003; Shirahashi et al.
2004; Schwartz et al. 2005; Baharvand et al. 2006; Duan
et al. 2007; Chiao et al. 2008; Basma et al. 2009) mimic
processes taking place during gastrulation, thereby pro-
viding signals necessary for the induction of hepatocyte
development. Subsequent plating of cells and treatment
with exogenous factors resulted in the generation of cells
exhibiting features of hepatic cells. However, the process
of EB formation is spontaneous, stochastic and results in
the development of diverse cell types. Alternatively, staged
protocols starting from monolayer cultures were exploited
more recently. These protocols usually involve as a ﬁrst
step the generation of DE cells from hESCs, which are
characterized by DE-speciﬁc Sox-17 and FoxA2 (HNF-3a)
co-expression (D’Amour et al. 2005). DE formation has
been obtained by cultivation of hESCs for usually 3–4 days
at low serum in the presence of activin A alone (Agarwal
et al. 2008) or in combination with insulin–transferrin–
selenium (ITS; Cai et al. 2007; Song et al. 2009), by the
addition of sodium butyrate (Hay et al. 2008b; Duan et al.
2010), Wnt3a (Hay et al. 2008a) or FGF2 (Brolen et al.
2010). In some protocols, inhibition of activin effects by
serum was antagonized by phosphatidylinositol 3-kinase
(PI3 K) inhibitors (McLean et al. 2007; Shiraki et al.
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1232008). Efﬁcient DE formation was also accomplished by
combining activin A, BMP2, FGF2 and a PI3 K inhibitor
(Touboul et al. 2010). Subsequently, in most protocols
hepatic speciﬁcation from DE was shown to be stimulated
by supplementation with FGF and BMP proteins for sev-
eral days. Finally, the development of hepatic progenitors
to more mature hepatocytes was achieved by treatment
with additional growth factors such as hepatocyte growth
factor (HGF), dexamethasone (Dex) and oncostatin M
(OSM).
Cell-to-cell interactions are important both in the
developing and the mature adult liver. Therefore, co-cul-
ture of differentiating liver cells with different cell types
was tested for its capacity to improve hepatic differentia-
tion of hESCs. For example, co-culture with mouse
embryonic stromal (STO) cells allowed for the expansion
of hepatic progenitor cells (Zhao et al. 2009a), and co-
culture with a mesoderm-derived mouse cell line (M15)
favoured expression of liver cell markers in differentiated
cells (Shiraki et al. 2008). Similarly, co-cultivation with a
murine mesenchymal cell line derived form foetal liver
(MLSgt20) promoted hepatic maturation of alpha-foeto-
protein (AFP)-positive cells (Ishii et al. 2010). In one
study, human foetal liver stromal cells genetically manip-
ulated to secret human FGF-2 were used as feeder cells for
hepatic speciﬁcation of DE cells (Pei et al. 2009). In
addition to co-culture with human and non-human cells,
growth of differentiating cells on extracellular matrices has
been shown to be beneﬁcial for hepatic differentiation. For
example, laminin, Matrigel and collagen matrices were
tested under 2D conditions (Ishii et al. 2008) with the best
effects observed with Matrigel. To mimic 3D conditions of
hepatic differentiation, collagen type 1 scaffolds as well as
poly-amino-urethane (PAU)-coated polytetraﬂuoroethyl-
ene (PTFE) fabrics have been used (Baharvand et al. 2006;
Soto-Gutierrez et al. 2006).
Because hESC-derived hepatocyte differentiation is still
not efﬁcient, enrichment strategies may be necessary to
obtain hepatocyte cultures of adequate purity, but lineage
selection has been applied only rarely. This might be due to
the fact that the hepatocyte identity can be hardly linked to
the exclusive expression of a single gene, but rather to a
speciﬁc transcriptional network. For example, the selection
of cells expressing an AFP promoter-driven reporter gene
resulted in hepatic cell populations that showed only low
levels of liver-speciﬁc transcripts, such as albumin, tyro-
sine aminotransferase and tryptophan 2, 3-deoxygenase
(Ishii et al. 2008). This is probably due to the fact that AFP
gene expression is not restricted to DE cells from which
hepatocytes arise, but also to extra-embryonic endoderm.
Other selection strategies for hepatic cells were based on
‘‘genetic’’ approaches, such as the use of albumin or alpha-
1-antitrypsin (AAT) promoter-driven reporter systems
(Lavon et al. 2004; Duan et al. 2007). On the other hand, a
selection strategy based on FACS sorting of differentiated
cells for the presence of the surface asialoglycoprotein
receptor 1 (ASGPR1) allowed the enrichment of hepato-
cyte-like cells. Secretion of albumin, urea and AAT as well
as expression and activity of the CYP450 proteins by
sorted cells reached levels near to those observed in pHHs
(Basma et al. 2009).
Characteristics of hESC-derived hepatocyte-like cells
In the past, derivation of hepatocytes from diverse (stem)
cell types has been reported. Hengstler et al. addressed the
problem of over-interpreting stem cell-derived cells as
‘‘hepatocytes’’ and suggested a minimal set of functions
that are necessary to deﬁne ‘‘true’’ hepatocytes: (1)
metabolism of xenobiotics and endogenous substances
(hormones and ammonia), (2) synthesis and secretion of
albumin, clotting factors, complement, transporter proteins,
bile, lipids and lipoproteins and (3) storage of glucose
(glycogen), fat soluble vitamins A, D, E and K, folate,
vitamin B12, copper and iron (Hengstler et al. 2005).
Furthermore, the comparison of stem cell-derived hepato-
cyte-like cells with primary hepatocytes was suggested to
be mandatory.
More recently, a list of criteria for characterization of
‘‘liver cells’’ derived from various stem cell sources has
been recommended (Sancho-Bru et al. 2009). Although
these criteria aim at the production of pure and standard-
ized hepatocyte populations for future clinical use, they
may be also applicable to the characterization of hepato-
cytes for in vitro toxicology applications. The list includes
parameters for characterization of cells during stages of
hepatic differentiation, criteria for ultrastructural evalua-
tion as well as a panel of functional tests. Since several
‘‘hepatocyte’’ markers and functions are also exhibited by
other than liver cells (e.g. expression of certain CYP450
genes, glycogen storage, etc.), the authors recommend to
demonstrate co-expression of hepatocyte markers in the
same cell and to perform several functional tests to
unambiguously prove hepatocyte identity of the differen-
tiated cell population (Sancho-Bru et al. 2009).
Cells derived from hESCs have been analysed in vitro
for hepatic properties, including morphological and ultra-
structural features as well as gene expression and func-
tional characteristics. In some studies, the ability of hESC-
derived hepatocyte-like cells to repopulate mouse livers
was also investigated (Agarwal et al. 2008; Basma et al.
2009; Touboul et al. 2010). Although, in general, hepato-
cyte-like cells exhibited some typical hepatic characteris-
tics, quantitative comparative analyses of hESC-derived
hepatic cells with pHHs for metabolic functions critical for
drug metabolism were only performed in a few studies.
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and distinct round nuclei typical for hepatocytes in
hESC-derived cells. In addition, hepatocyte-speciﬁc
ultrastructural characteristics, such as prominent nucleoli,
well-developed Golgi apparatus, abundance of mito-
chondria and lysosomes, glycogen granules and rough,
smooth endoplasmic reticulum as well as cell-junctional
complexes and biliary canaliculi were observed (Ba-
harvand et al. 2006; Baharvand et al. 2008; Shiraki et al.
2008; Basma et al. 2009; Pei et al. 2009; Sasaki et al.
2009).
The process of hepatic differentiation of hESCs has been
characterized by analysing transcripts and proteins typical
for speciﬁc stages of hepatocyte development (reviewed in
Snykers et al. 2009). The differentiation of DE cells was
determined by transcript levels of FoxA2, Sox17 and par-
tially CXCR4. Presence of hepatocyte progenitors was
veriﬁed by the presence of AFP at transcript and protein
levels, usually in combination with albumin, a marker of
more mature hepatic cells. In one study, bi-potential
hepatic progenitor cells derived from sorted N-cadherin-
positive hepatic endoderm and expressing AFP (but not
albumin) were generated. These cells showed some pro-
liferative capacity as determined by Ki67 gene expression
and expressed the putative hepatoblast markers EpCAM
and CD133 as well as the bile duct lineage markers KRT7
and KRT19 (Zhao et al. 2009a). Finally, in most studies
maturation of hepatocytes was veriﬁed by the presence of
combinations of liver-speciﬁc transcripts and proteins, such
as albumin, a1-antitrypsin, certain cytokeratins, HNF-4,
tyrosine aminotransferase (TAT), CYP450s, transthyretin
(TTR) and others (for overview see Snykers et al. 2009).
However, the deﬁnition of the hepatic identity of hESC-
derived cells has been complicated by the fact that the
protocols used for hepatic differentiation generally resulted
in a mixture of cell types. Some markers considered as
‘‘liver-speciﬁc’’, such as AFP, are also present in other cell
types. AFP gene expression declines during hepatocyte
differentiation and is absent from mature adult hepatocytes.
However, in several studies, AFP gene expression was still
detected at the end of the in vitro differentiation process,
indicating that the hESC-derived hepatocyte-like cells
represent an immature phenotype (Baharvand et al. 2006;
Hay et al. 2007; Hay et al. 2008b; Ishii et al. 2008). Other
genes, such as those for CK18 or TTR, are also expressed
at several stages of hepatic development in vitro, and
without the analysis of additional markers the correct
assignment of the cell population to a speciﬁc develop-
mental stage is not possible. Therefore, detection of
simultaneous expression of hepatocyte-speciﬁc genes, such
as transcription factors and/or hepatic enzymes, is neces-
sary to ensure a genuine hepatic phenotype of the differ-
entiated cells.
To determine the functionality of hESC-derived hepa-
tocyte-like cells, tests for liver-speciﬁc metabolic functions
were performed, frequently including storage of glycogen,
albumin secretion and uptake and release of indocyanine
green (ICG; reviewed in Baxter et al. 2010). In several
studies, hepatocyte-like cells were tested for other liver cell
functions, for example urea synthesis and secretion,
secretion of additional serum proteins such as a1-anti-
trypsin (AAT) or coagulation factors, low-density lipo-
protein (LDL) uptake, gluconeogenesis or entry of a
pseudotyped hepatitis C virus into cells (Schwartz et al.
2005; Soto-Gutierrez et al. 2006; Cai et al. 2007; Baharv-
and et al. 2008; Fletcher et al. 2008; Hay et al. 2008b;
Basma et al. 2009; Zhao et al. 2009a).
However, a validated standardized protocol for differ-
entiation of hESCs toward hepatocytes is currently not
available, exact parameters that deﬁne the functionality of
hepatic cells are lacking and the data differ among studies.
Another problem is the high variability of cellular refer-
ence systems used by different authors and the poor
description of these systems in some studies. Reference
systems frequently used are hepatoma cell lines (such as
HepG2, HuH7 and Alexander cells), foetal and adult liver
cell extracts, and rat or human pHHs. Although pHHs were
regularly used, data on the origin of pHHs (e.g. freshly
isolated vs. cryoconserved, individual donor vs. hepatocyte
pool, in-house prepared cells vs. commercially acquired
cells, etc.), methods for hepatocyte cultivation and data on
age, purity and characteristics of the speciﬁc hepatocyte
preparation are often lacking. These problems complicate
the comparison of hESC-derived hepatocyte-like cells with
respect to their liver cell characteristics and hamper the
assessment, whether speciﬁc protocols may be useful for
efﬁcient differentiation of functional hepatocytes from
hESCs.
In summary, there has been some progress in the
establishment of protocols for the generation of hepato-
cyte-like cells from hESCs over the past decade. It is still a
matter of debate to what degree stem cell-derived hepato-
cytes will have to resemble primary human hepatocytes
before they can be used to reliably predict metabolite
generation and (de)toxiﬁcation (Hengstler et al. 2005). In
any case, the establishment of a validated and standardized
battery of tests to assess the identity and functionality of
hepatocyte-like cells would be a major advance in this ﬁeld
(see also below).
Derivation of hepatocyte-like cells from hiPSCs
The development of reprogramming strategies offers the
opportunity to generate hepatic cells from hiPSCs, which
could have a major impact on human disease research,
regenerative medicine and drug development. hiPSC-
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polymorphic variants as well as from patients suffering
from speciﬁc metabolic diseases would allow the investi-
gation of individual drug risks that are not accessible with
other techniques. Moreover, patient-speciﬁc hiPSC-derived
hepatocytes would be available for cell therapeutic
applications.
The generation of hepatocyte-like cells from hiPSCs
was shown in several studies (Song et al. 2009; Liu et al.
2010; Si-Tayeb et al. 2010b; Sullivan et al. 2010; Touboul
et al. 2010). Independent of the origin of donor cells and
reprogramming factors, hiPSCs were generally able to
differentiate into hepatocyte-like cells that expressed genes
in a liver-speciﬁc manner and exhibited certain hepatocyte
functions. In these proof-of-concept studies, the efﬁciency
of differentiation towards hepatocyte-like cells was com-
parable to hESCs and only subtle differences in gene
expression and metabolic capacities of differentiated
progeny were observed between hESCs und hiPSCs. Minor
differences were also observed in hepatocyte-like cells
derived from different hiPSC lines probably due to the
heterogeneity of donor cells used for hiPSC generation.
However, expression levels of genes for liver-speciﬁc
enzymes and metabolic activities were only marginally
tested, and a more comprehensive and comparative anal-
ysis of hiPSC-derived hepatic cells with respect to impor-
tant liver cell characteristics remains to be done.
In general, hiPSCs have been mainly produced from
ﬁbroblasts. In one study, however, pHHs were exploited as
starting material for hiPSC generation and subsequent
hepatic differentiation (Liu et al. 2010). When compared to
MSC-derived hiPSCs, reprogramming of pHHs resulted in
the accelerated formation of hiPSC colonies, but the
hepatic differentiation capacity of hepatocyte-derived
hiPSCs did not differ from that of hESC- and ﬁbroblast-
derived hiPSCs. However, an extensive analysis of hepatic
characteristics as well as quantitative investigations of
differentiation capacities has not been performed. In view
of recent results of the epigenetic memory of iPS cells
(Kim et al. 2010b), it will be interesting to explore whether
hepatocyte-derived hiPSCs might allow for a more effec-
tive generation of hepatocyte-like cells, which exhibit a
higher maturation level as hESC-derived hepatocyte-like
cells. In addition, use of pHH-derived hiPSCs for gener-
ating patient-speciﬁc hepatocytes may also be of interest
for developing disease models, since, for example, somatic
mutations important for development and progression of
liver cell tumours are acquired in the liver only and cannot
be mirrored by cells generated from ﬁbroblast-derived
hiPSCs (Bluteau et al. 2002).
Recently, hiPSCs were generated from patients with
inherited metabolic disorders of the liver (Rashid et al.
2010). The cells were differentiated into the hepatic lineage
resulting in hepatocyte-like cells that showed some features
of mature hepatocytes and, most importantly, exhibited
molecular characteristics of the diseased phenotypes (a1-
antitrypsin deﬁciency, familial hypercholesterolaemia and
glycogen storage disease type 1a, respectively). This proof-
of-concept study provided evidence that multiple liver
disease-speciﬁc cell lines can be generated and that hepa-
tocytes differentiated from these hiPSCs may be useful for
modelling liver diseases in vitro and in a patient-speciﬁc
manner.
Requirements for the use of pluripotent stem
cell-derived hepatocyte-like cells in safety
pharmacology and toxicology
As mentioned earlier, drug-induced liver injury is a multi-
factorial disorder commonly due to CYP450-dependent
formation of reactive metabolites that directly exert hepa-
totoxicity or form adducts with liver proteins triggering an
immune response. In addition, hepatotoxicity can be
caused by interference with mitochondrial function, inhi-
bition of xenobiotic metabolism or disturbance of bile acid
transport. In many cases, liver toxicity only occurs after
prolonged exposure to drugs. It is still a matter of debate
whether hepatocytes in vitro might be able to model
chronic hepatotoxicity. In any case, hepatocyte populations
of reproducible quality, which can be cultured for pro-
longed periods of time and which show liver cell-speciﬁc
functions comparable to those of pHHs would be a suitable
in vitro system to investigate potential hepatotoxic drug
effects.
One of the most critical parameters for the potential use
of hPSC-derived hepatocyte-like cells in safety pharma-
cology and toxicology is their ability to metabolize drugs
by phase I enzymes of the CYP450 family. In addition, the
presence and functionality of phase II enzymes involved in
drug conjugation and of transporter proteins responsible for
elimination and clearance of drug metabolites as well as for
uptake of drugs will be important for the functionality of
stem cell-derived hepatocyte-like cells in vitro. So far, data
on the activity of these enzymes in hPSC-derived hepato-
cyte-like cells are still fragmentary. While in some earlier
studies the activity of certain CYP450 subtypes in hESC-
derived hepatocyte-like cells was determined (Rambhatla
et al. 2003; Schwartz et al. 2005), data on CYP450 gene
expression patterns are lacking. In some studies, CYP450
expression at the transcript and protein level was analysed
and metabolic activity of the CYP450 enzymes was
determined in several studies.
Obviously, there are broad differences in CYP450 gene
expression between hESC-derived hepatocyte-like cells
generated in different studies. An example is the expression
of the Cyp3A4 gene whose product plays a central role in
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certain drugs. In some studies, CYP3A4 transcripts were
reported to be present at up to 1,000-fold lower abundance
in hESC-derived hepatocyte-like cells than in human liver
or pHHs even after CYP induction (Ek et al. 2007; Shiraki
et al. 2008; Brolen et al. 2010), whereas Basma and col-
leagues found an only threefold lower Cyp3A4 transcript
level in the hESC-derived progeny compared to pHHs
(Basma et al. 2009). This discrepancy is probably not
solely due to the hepatocyte enrichment step performed in
the latter study, because sorting for ASGPR1-positive cells
only yielded about twofold enrichment of hepatocyte-like
cells according to albumin secretion data. Other reasons
may include the use of different hESC lines (KhES-1,
SA02 or SA167 and H1, respectively), different protocols
used for in vitro differentiation or, most likely, the quality
of pHHs used as reference cells.
In several studies, metabolic activities of CYP450
enzymes present in hESC-derived hepatocyte-like cells
were analysed (Hay et al. 2008a; Basma et al. 2009; Moore
and Moghe 2009; Zhao et al. 2009a; Brolen et al. 2010;
Touboul et al. 2010). CYP450 activity was generally
detected, but with considerable variations among studies.
This can be illustrated by data on Cyp1A2 activity that was
determined in at least six studies by either EROD assay or
measurement of phenacetin metabolization. In an early
study on hepatic differentiation of hESCs, CYP1A2
activity in hESC-derived hepatocyte-like cells was shown
to be comparable to that in pHHs (Rambhatla et al. 2003).
Interestingly, the results of the EROD assay presented in
this study were comparable to those reported very recently
by another group who applied a more speciﬁc differentia-
tion protocol involving several hepatic growth factors
(Moore and Moghe 2009). In two studies using the EROD
assay under similar conditions, Cyp1A2 activity was
shown to be 4 and 40% of that measured in pHHs,
respectively (Hay et al. 2008a; Basma et al. 2009). In
contrast, in another study involving a multi-stage differ-
entiation protocol (Brolen et al. 2010) phenacetin metab-
olization by Cyp1A was only slightly higher in hESC-
derived hepatocyte-like cells than in HepG2 cells. HepG2
cells are known to exert about 100-fold lover Cyp1A2
activity than pHHs (Westerink and Schoonen 2007). In
addition to differences in cell lines and the differentiation
protocol used in these studies, speciﬁcities in the experi-
mental settings and the quality of the reference cells may
account for the differences in the reported CYP450 activ-
ities in relation to pHHs.
It should be noted that standardized data on the char-
acteristics and the quality of the pHHs used as a reference
system are lacking from most studies. Therefore, the rea-
sons for the differences observed in gene expression and
enzyme activities of liver cell proteins remain elusive. In
many cases, only comparison within their own studies was
of interest to the authors (e.g. production of hepatocyte
enzymes at different stages of the differentiation process).
Consequently, data were often given in a format (e.g. lg/
well), which makes it impossible to compare different
studies and to draw conclusions on the suitability of a
speciﬁc protocol for deriving functional hepatocytes from
hPSCs. Therefore, presenting data in a format suitable for
inter-study comparisons would be desirable. Moreover,
data for assessment of the quality of the reference cells
(usually pHHs) should be included. For example, urea
secretion has been suggested as a reproducible and easy to
measure factor with signiﬁcance for quality of hepatocytes
used in bioreactors (Pless et al. 2006).
While some efforts were undertaken to prove the pres-
ence and functionality of phase I enzymes in hESC-derived
hepatocyte-like cells, the presence and activity of phase II
enzymes and transporter protein activity in these cells was
investigated in only a few studies. For example, So ¨derdahl
et al. investigated the presence of glutathione S-transfer-
ases (GSTs) in hepatocyte-like cells (So ¨derdahl et al.
2007). While presence of the GSTA1-1 subunit was clearly
shown in hESC-derived hepatic cells, GSTM-1 was only
weakly expressed in hepatocyte-like cells derived from
four of ﬁve hESC lines and GSTP-1 gene expression was
not detectable. However, general GST activity as measured
by catalytic activity towards 1-chloro-2,4-dinitrobenzene
(CDNB) was comparable to that in pHHs and clearly
exceeded GST activity of the hepatoma cell line HepG2.
In a recent study, a staged protocol was used to obtain
hepatocyte-like cells of relatively high purity (about 90%
expressing ALB or AAT, and 60% are ASGPR1-positive at
days 20–22; Duan et al. 2010). Differentiated cells
expressed the genes coding for phase I and phase II liver
enzymes, transporter proteins and nuclear receptors critical
in regulating the expression of metabolizing enzymes. The
major pathways of bufuralol metabolism were shown to be
active in these cells and several previously unknown met-
abolic pathways for bufuralol metabolization were identi-
ﬁed. Although metabolites of bufuralol were produced in
hESC-derived hepatocyte-like cells to a lower extent than
in pHHs, hydroxylation of phenacetin (Cyp1A2) and buf-
uralol (CYP2D6) was performed at a comparable rate at
48 h post-drug addition. These data are encouraging since,
for the ﬁrst time, it was shown that hESC-derived hepatic
cells indeed have the capacity to metabolize drugs in a
manner comparable to pHHs.
Until now, there are only limited data available on long-
term cultivation of hPSC-derived hepatocyte-like cells. In
only a few studies, cells were differentiated for more than
20–30 days and data on stability of gene expression or
metabolic function after prolonged culture were only
occasionally reported. However, this would be important,
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cation over an extended period of time or reiterated
exposure. In a few studies, extended differentiation times
resulted in increased hepatocyte-speciﬁc transcript and
protein levels suggesting further maturation in vitro. For
example, AAT secretion by hepatocyte-like cells increased
nearly sixfold from day 31–43 after starting differentiation
although secretion of both albumin and AAT were low in
comparison with pHHs (Shirahashi et al. 2004). In another
report, albumin transcript levels doubled, whereas AFP
gene expression markedly dropped between day 18 and 50
of hepatocyte differentiation (Shiraki et al. 2008). More-
over, Cyp3A4 transcript levels increased about 10-fold in
this period. Although both albumin and Cyp3A4 levels
were quite low when compared to foetal and adult human
hepatocytes in this study, differentiation and culture for
extended periods of time may allow for further hepatocyte
maturation.
On the other hand, it will be critical to investigate
whether hPSC-derived hepatocyte-like cells will undergo
de-differentiation and lose their mature phenotype when
cultured for several days or weeks. Recently, Kheatni and
Bhatia developed a miniaturized, multi-well culture system
with an optimized microscale architecture that facilitated
extended culture of pHHs for several weeks as determined
by analysis of several liver cell-speciﬁc functions including
phase I/phase II enzyme gene expression (Khetani and
Bhatia 2008). Application of such a system to hepatic
differentiation of hPSCs could not only allow for longer
cultivation, but also help to scale down cell culture to
formats required for HTP-based methods in the pharma-
ceutical industry. However, cryopreservation of hPSC-
derived hepatocytes has not been reported yet.
Future challenges of the application of pluripotent stem
cell-derived hepatocytes in toxicology
Initial progress has been achieved in the establishment of
test systems for hepatotoxicity using hepatic cells derived
from hPSCs. However, the following problems have to be
solved before these cells can be applied in routine phar-
maco-toxicology.
(i) Immature phenotype of hPSC-derived hepatocytes The
immature phenotype and inadequate expression of genes
coding for enzymes critical for liver cell metabolism is one
of the main problems of hPSC-derived hepatocyte-like
cells. To establish novel models for predicting liver cell
toxicity with higher conﬁdence than other in vitro systems,
further improvements in differentiation protocols are nec-
essary. Since murine ESCs fully mature after transplanta-
tion into syngeneic animals, it is likely that also hESCs
have the full hepatic developmental potential. Therefore,
reproduction of a liver-speciﬁc environment may be nec-
essary for hepatocyte maturation in vitro. This may be
obtained by ECM-supported 3D-co-culture systems. For
example, improved survival and differentiation of foetal
human hepatocytes into hepatocyte-like cells have been
shown in 3D culture systems under constant perfusion
(Ring et al. 2010; Schmelzer et al. 2010). Co-culture with
liver epithelial cells and/or vascular endothelial cells may
also have a positive impact on ESC-derived liver cell dif-
ferentiation and maturation (e.g. Moore et al. 2008b). In
addition, it will be necessary to establish culture conditions
that facilitate the development and maintenance of mature
phenotypes for a period long enough to perform pharma-
cological and toxicological studies.
(ii) Lack of deﬁned and validated endpoints of hepatic
differentiation and maturation The application of hPSC-
derived hepatocytes will require deﬁned endpoints for
hepatic differentiation and maturation in vitro. Parameters
and functional tests appropriate to standardize hepatocyte
differentiation and to compare differentiation procedures
have been proposed, but are not validated until now. Val-
idation studies should include liver-speciﬁc gene expres-
sion and several functional tests including analyses of
metabolizing enzyme activities.
(iii) Requirement of standardized reference systems for
differentiated hepatic cells At present, pHHs are well-
established reference cells, but their metabolic capacity can
strongly differ among preparations (Hewitt et al. 2007).
Consequently, it is currently difﬁcult to assess to what
extent hPSC-derived hepatocyte-like cells exhibit charac-
teristics of liver cells when compared to pHHs. Therefore,
standardized and validated parameters deﬁning the quality
of reference hepatocytes are needed. In this context, it may
be of interest to establish a database of global pHH
expression proﬁles that could be useful to classify speciﬁc
populations of hepatocyte-like cells. A corresponding sys-
tem has been successfully developed for pluripotent hES
and hiPS cells from diverse sources and laboratories that
can be used to assess the pluripotent phenotype (‘‘stem-
ness’’) of human stem cells (Mu ¨ller et al. 2008).
(iv) Generation of hepatocytes at high numbers To meet
the requirements of the pharmaceutical industry, differen-
tiation and cultivation of hepatocyte-like cells have to be
scaled up. Human ESCs can be cultured in stirred-sus-
pension bioreactors (reviewed in Kehoe et al. 2010) and an
experimental approach for the differentiation of hESCs into
deﬁnitive endoderm in a microcarrier bioreactor has been
reported (Lock and Tzanakakis 2009). It will be necessary
to explore similar approaches for the differentiation of
hESCs and hiPSCs into the hepatic lineage. For HTP
applications, test systems also need to be miniaturized.
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standardization Studies on hepatic differentiation of
hESCs were performed using only about 20 of the more
then 1,000 existing hESC lines, and only eight lines were
used in more than one single study so far. Similarly, only a
limited number of hiPSC lines were tested for their hepatic
differentiation potential. Several hESC lines showed a
different potential for hepatic differentiation (Ek et al.
2007). It is still an open question, whether protocols
established and optimized for a speciﬁc cell line can be
successfully applied to other cell lines. Since provision of
cell lines representing a multitude of metabolic phenotypes
would be one of the utmost advantages of using hPSC-
derived hepatocytes, investigation of this question is of
major interest.
In conclusion, the recent progress in the establishment of
hepatic differentiation of human ES and iPS cells is
encouragingwiththeperspectivetoimplementnovelhuman
cell-based in vitro assays for toxicology. The test systems
may have the potential to predict hepatotoxicity already in
early phases of drug development. They would reduce drug
attrition,may lead to cost reduction indevelopment of novel
drugs and to improved safety proﬁles of pharmaceuticals.
However, before such systems can be implemented into
routine toxicity testing, robust and reproducible hepatic
differentiation protocols have to be developed and the
problems discussed above have to be solved.
Future Perspectives
Since the establishment of the ﬁrst human pluripotent stem
cell lines more than a decade ago the therapeutic potential
of stem cells has been extensively discussed. Only in the
more recent past, the unique potential of pluripotent stem
cells in drug research and toxicology was realized. Plu-
ripotent human stem cells could offer many beneﬁts to this
ﬁeld, especially the perspective of an unlimited supply with
human cells of well-deﬁned origin, homogeneous charac-
teristics and relevance to the human situation. While tox-
icological assays using murine PSCs are already performed
routinely, human PSCs are still under investigation with
respect to their suitability for these applications. However,
proof-of-principle has been provided that these cells could
make a valuable contribution to the technology platforms
in safety pharmacology and toxicology. Especially in the
ﬁeld of developmental toxicology, hESCs represent a
unique human-speciﬁc test system, although methodical
questions remain to be solved, relevant endpoints must be
identiﬁed and HTP screening methods still have to be
developed.
With respect to cardio- and hepatotoxicology the estab-
lishment of reproducible and inexpensive differentiation
protocols that are amenable to HTP platforms is still a
challenge. However, speciﬁcally for cardio- and hepato-
toxicology, but also for neurotoxicology studies patient-
and disease-speciﬁc hiPSCs offer enormous opportunities
for the development of in vitro systems that can signiﬁ-
cantly improve drug safety and contribute to acceleration of
drug development.
One of the most important problems related to the use
of iPS cells in pharmaco-toxicology, the potentially
tumourigenic status of pluripotent stem cells, will even-
tually be overcome by recent innovations. Instead of
reprogramming to pluripotency, several studies demon-
strated lineage reprogramming or transcription factor-
based trans-differentiation of cells from one lineage to the
other. This direct lineage reprogramming could avoid the
potentially tumourigenic state of ES or iPS cells and the
contamination of reprogrammed cells by residual plurip-
otent stem cells (reviewed in Wobus 2010). Such direct
conversion of ﬁbroblasts into skeletal muscle cells by the
master regulator gene MyoD was already shown in the
late 1980s (Davis et al. 1987). Recently, murine ﬁbro-
blasts could be reprogrammed by speciﬁc transcription
factors into neural (Vierbuchen et al. 2010) or cardiac
(Ieda et al. 2010) cells. Previous studies have shown the
conversion of B lymphocytes into macrophages by CEP/B
expression (Xie et al. 2004). In addition, a switch from
the exocrine to the endocrine lineage has been demon-
strated in vivo by adenovirus transfection of acinar cells
by transcription factors involved in pancreatic differenti-
ation (Pdx1, Ngn3, MafA) resulting in the induction of
insulin-producing beta cells (Zhou et al. 2008). This new
strategy may also be an attractive alternative for the
generation of human ‘‘induced cardiomyocytes’’ (as dis-
cussed in Passier and Mummery 2010) or ‘‘induced
hepatocytes’’. The prospect of producing specialized
human cells without the need to transiently reprogramme
somatic cells into a pluripotent, potentially tumourigenic
state is very promising.
Another strategy would be partial reprogramming of
specialized cells to a state of higher plasticity (dediffer-
entiation), resembling progenitor cells with multi-potent
capacities. Such cell systems would allow developmental
toxicological analyses also on tissue-speciﬁc progenitor
cell populations.
Future studies have to analyse the preconditions and
consequences of these reprogramming strategies for human
cells, such as the role of the cell type of origin, epigenetic
status of donor cells as well as the stability and function-
ality of the trans-differentiated or dedifferentiated cells.
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